<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">10860</article-id><article-id pub-id-type="doi">10.7554/eLife.10860</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Registered Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Registered report: IDH mutation impairs histone demethylation and results in a block to cell differentiation</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-40132"><name><surname>Richarson</surname><given-names>Adam D</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-40133"><name><surname>Scott</surname><given-names>David A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-40134"><name><surname>Zagnitko</surname><given-names>Olga</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-40135"><name><surname>Aza-Blanc</surname><given-names>Pedro</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-40136"><name><surname>Chang</surname><given-names>Chih-Cheng</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" id="author-17399"><name><surname>Russler-Germain</surname><given-names>David A</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1009-2247</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><collab>Reproducibility Project: Cancer Biology</collab><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf7"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Cancer Metabolism Facility</institution>, <institution>Sanford Burnham Prebys Medical Discovery Institute</institution>, <addr-line><named-content content-type="city">La Jolla</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">Functional Genomics Core</institution>, <institution>Sanford Burnham Prebys Medical Discovery Institute</institution>, <addr-line><named-content content-type="city">La Jolla</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><label>3</label><institution>Washington University School of Medicine</institution>, <addr-line><named-content content-type="city">St Louis</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Davidson</surname><given-names>Irwin</given-names></name><role>Reviewing editor</role><aff id="aff4"><institution>Institut de Génétique et de Biologie Moléculaire et Cellulaire</institution>, <country>France</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Iorns</surname><given-names>Elizabeth</given-names></name><aff><institution>Science Exchange</institution>, <addr-line><named-content content-type="city">Palo Alto</named-content></addr-line>, <country>United States</country></aff></contrib><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Gunn</surname><given-names>William</given-names></name><aff><institution>Mendeley</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff></contrib><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Tan</surname><given-names>Fraser</given-names></name><aff><institution>Science Exchange</institution>, <addr-line><named-content content-type="city">Palo Alto</named-content></addr-line>, <country>United States</country></aff></contrib><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Lomax</surname><given-names>Joelle</given-names></name><aff><institution>Science Exchange</institution>, <addr-line><named-content content-type="city">Palo Alto</named-content></addr-line>, <country>United States</country></aff></contrib><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Perfito</surname><given-names>Nicole</given-names></name><aff><institution>Science Exchange</institution>, <addr-line><named-content content-type="city">Palo Alto</named-content></addr-line>, <country>United States</country></aff></contrib><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Errington</surname><given-names>Timothy</given-names></name><aff><institution>Center for Open Science</institution>, <addr-line><named-content content-type="city">Charlottesville</named-content></addr-line>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><email>fraser@scienceexchange.com</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>14</day><month>03</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>5</volume><elocation-id>e10860</elocation-id><history><date date-type="received"><day>18</day><month>08</month><year>2015</year></date><date date-type="accepted"><day>15</day><month>02</month><year>2016</year></date><fn><p><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Ward</surname><given-names>PS</given-names></name><name><surname>Kapoor</surname><given-names>GS</given-names></name><name><surname>Rohle</surname><given-names>D</given-names></name><name><surname>Turcan</surname><given-names>S</given-names></name><name><surname>Abdel-Wahab</surname><given-names>O</given-names></name><name><surname>Edwards</surname><given-names>CR</given-names></name><name><surname>Khanin</surname><given-names>R</given-names></name><name><surname>Figueroa</surname><given-names>ME</given-names></name><name><surname>Melnick</surname><given-names>A</given-names></name><name><surname>Wellen</surname><given-names>KE</given-names></name><name><surname>O’Rourke</surname><given-names>DM</given-names></name><name><surname>Berger</surname><given-names>SL</given-names></name><name><surname>Chan</surname><given-names>TA</given-names></name><name><surname>Levine</surname><given-names>RL</given-names></name><name><surname>Mellinghoff</surname><given-names>IK</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group> . <year>2012</year> . <article-title>IDH mutation impairs histone demethylation and results in a block to cell differentiation</article-title> .<source>Nature</source> . <volume>483</volume> : <fpage>474</fpage> – <lpage>478</lpage> . doi: <pub-id pub-id-type="doi">10.1038/nature10860</pub-id> .</mixed-citation> </p></fn></history><permissions><copyright-statement>© 2016, Richarson et al</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Richarson et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-10860-v1.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.10860.001</object-id><p>The <ext-link ext-link-type="uri" xlink:href="https://osf.io/e81xl/wiki/home/">Reproducibility Project: Cancer Biology</ext-link> seeks to address growing concerns about reproducibility in scientific research by conducting replications of selected experiments from a number of high-profile papers in the field of cancer biology. The papers, which were published between 2010 and 2012, were selected on the basis of <ext-link ext-link-type="uri" xlink:href="https://osf.io/e81xl/wiki/studies/">citations and Altmetric scores</ext-link> (Errington et al., 2014). This Registered Report describes the proposed replication plan of key experiments from “IDH mutation impairs histone demethylation and results in a block to cell differentiation” by Lu and colleagues, published in Nature in 2012 (Lu et al., 2012). The experiments that will be replicated are those reported in Figures 1B, 2A, 2B, 2D and 4D. Lu and colleagues demonstrated that expression of mutant forms of IDH1 or IDH2 caused global increases in histone methylation and increased levels of 2 hydroxyglutarate (Figure 1B). This was correlated with a block in differentiation (Figures 2A, B and D). This effect appeared to be mediated by the histone demethylase KDM4C (Figure 4D). The Reproducibility Project: Cancer Biology is a collaboration between the <ext-link ext-link-type="uri" xlink:href="https://cos.io/">Center for Open Science</ext-link>and <ext-link ext-link-type="uri" xlink:href="https://www.scienceexchange.com/">Science Exchange</ext-link>, and the results of the replications will be published by <italic>eLife</italic>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.10860.001">http://dx.doi.org/10.7554/eLife.10860.001</ext-link></p></abstract><kwd-group kwd-group-type="author-keywords"><title>Author Keywords</title><kwd>IDH mutation</kwd><kwd>2HG metabolism</kwd><kwd>reproducibility project: cancer biology</kwd><kwd>methodology</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research Organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution>Laura and John Arnold Foundation</institution></institution-wrap></funding-source><principal-award-recipient><institution>The Reproducibility Project: Cancer Biology</institution></principal-award-recipient></award-group><funding-statement>The Reproducibility Project: Cancer Biology is funded by the Laura and John Arnold Foundation, provided to the Center for Open Science in collaboration with Science Exchange.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>elife-xml-version</meta-name><meta-value>2.5</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Mutations in the metabolic proteins IDH1 and IDH2 are associated with gliomas, acute myeloid leukemias, chondrosarcomas, intrahepatic cholangiocarcinomas, lymphomas, melanomas and colon, thyroid and prostate cancers (for review, see <xref ref-type="bibr" rid="bib8">Krell et al., 2013</xref>). Previous work has shown that these mutations change the specificity of the reaction catalyzed by IDH proteins; instead of producing α-ketoglutarate from isocitrate, they produce 2-hydroxyglutarate (2HG), a metabolite that can have oncogenic effects (<xref ref-type="bibr" rid="bib8">Krell et al., 2013</xref>; <xref ref-type="bibr" rid="bib12">McKenney and Levine, 2013</xref>; <xref ref-type="bibr" rid="bib16">Ward et al., 2010</xref>; <xref ref-type="bibr" rid="bib18">Xu et al., 2011</xref>; <xref ref-type="bibr" rid="bib19">Zhang et al., 2013</xref>). Lu and colleagues expand upon this work to identify a potential mechanism for how 2HG can effect major changes in cell behavior. They present evidence that 2HG interferes with global demethylation that is required for progenitor cells to complete terminal differentiation. Transfection of 3T3-L1 cells with the mutant forms of <italic>IDH1</italic> and <italic>IDH2</italic> that produce 2HG lead to an increase in global methylation levels and prevented normal in vitro differentiation into adipocytes. The 2HG-sensitive histone demethylase KDM4C appeared to be required for this process, as knockdown of KDM4C recapitulated the phenotype of 2HG production. Examination of glioma samples showed a correlation between <italic>IDH</italic> mutation status and level of overall methylation (<xref ref-type="bibr" rid="bib11">Lu et al., 2012</xref>). Taken together, Lu and colleagues’ findings help explain how mutations in IDH1 and IDH2 potentially interface with cancer development and progression.</p><p>In Figure 1B, Lu and colleagues examined the effects of mutations in <italic>IDH1</italic> and <italic>IDH2</italic> on global levels of methylation by transfecting mutant and wild type forms of the genes into 293T cells and using Western blot to assess the levels of various methylation markers. They also confirmed that introduction of the mutated forms of <italic>IDH1</italic> and <italic>IDH2</italic> correlated with increased intracellular levels of the oncometabolite 2HG. Their findings suggest that mutations in <italic>IDH1</italic> and <italic>IDH2</italic> correlate with increased levels of many methylation markers, and this key finding is replicated in Protocol 1.</p><p>In order to understand the effects of hypermethylation more fully, Lu and colleagues turned to an in vitro model of differentiation; when treated with appropriate signals, 3T3-L1 cells undergo epigenetic changes required for them to differentiation into adipocytes. In Figure 2A and B, they transfect undifferentiated 3T3-L1 cells with the wild type and mutant forms of IDH2 and assess the cells’ ability to differentiate into adipocytes, as determined by staining for lipid droplets with Oil-Red-O. While differentiated 3T3-L1 cells transfected with vector only or wild type <italic>IDH2</italic> showed robust Oil-Red-O staining, cells transfected with mutant <italic>IDH2</italic> did not, indicating a block in differentiation. qRT-PCR confirmed that cells transfected with mutant <italic>IDH</italic> variants did not express high levels of known adipocyte markers (Figure 2D). This key finding will be replicated in Protocol 2.</p><p>Lu and colleagues identified a histone demethylase, <italic>KDM4C</italic>, expressed as 3T3-L1 differentiation progressed, that appeared to be sensitive to 2HG. In Figure 4D, they use siRNAs to knock down levels of <italic>KDM4C</italic> in differentiating 3T3-L1 cells. Western blot analysis and Oil-Red-O staining confirmed that loss of KDM4C increased global methylation levels and inhibited differentiation. This key finding will be replicated in Protocol 3.</p><p>Several aspects of Lu’s findings have been corroborated by other work. Multiple groups have demonstrated that perturbations in IDH proteins alter methylation levels; overexpression of the <italic>IDH1</italic><sup>R132H</sup> allele in human tumor cells lines increased global histone methylation levels (<xref ref-type="bibr" rid="bib3">Duncan et al., 2012</xref>), exogenous <italic>IDH2</italic><sup>R140Q</sup> increased methylation levels in erythroleukemia progenitor cells (<xref ref-type="bibr" rid="bib7">Kernytsky et al., 2015</xref>) and an immortalized astrocyte cell line expressing <italic>IDH1</italic><sup>R132H</sup> also demonstrated increased levels of methylation (<xref ref-type="bibr" rid="bib14">Turcan et al., 2012</xref>). Members of the Thompson lab (authors of this study) have confirmed that expression of mutant variants of IDH proteins in 3T3-L1 cells blocked differentiation into adipocytes (<xref ref-type="bibr" rid="bib10">Londono Gentile et al., 2013</xref>; <xref ref-type="bibr" rid="bib17">Ward et al., 2013</xref>). Sasaki and colleagues have shown that mutant <italic>IDH1</italic> expression increased levels of methylation in mice (<xref ref-type="bibr" rid="bib13">Sasaki et al., 2012</xref>), while Akbay and colleagues published a similar observation for mutant forms of <italic>IDH2</italic> (<xref ref-type="bibr" rid="bib1">Akbay et al., 2014</xref>). This effect may even hold true for human patients, as there is a marked increase in H3K9me3 levels associated with <italic>IDH</italic> mutations in oligodendromas and high grade astrocytomas (<xref ref-type="bibr" rid="bib15">Venneti et al., 2013</xref>).</p></sec><sec id="s2" sec-type="materials|methods"><title>Materials and methods</title><p>Unless otherwise noted, all protocol information was derived from the original paper, references from the original paper, or information obtained directly from the authors. An asterisk (*) indicates data or information provided by the Reproducibility Project: Cancer Biology core team. A hashtag (#) indicates information provided by the replicating lab.</p><sec id="s2-1"><title>Protocol 1: Assessing the methylation status and 2HG production of 293T cells transfected with mutant forms of IDH1 and IDH2</title><p>This protocol describes how to transfect 293T cells with wild-type and mutant forms of IDH1 and IDH2 and assess levels of global methylation and 2HG production, as seen in Figure 1B and Supplemental Figure 1.</p><sec id="s2-1-1"><title>Sampling</title><list list-type="bullet"><list-item><p>Experiment will be repeated a total of 6 times for a minimum power of 80%. The metabolite data is qualitative, thus to determine an appropriate number of replicates to initially perform, sample sizes based on a range of potential variance was determined.<list list-type="bullet"><list-item><p>See &quot;power alculations' for details.</p></list-item><list-item><p>The metabolite data displayed in the bottom of Figure 1B were derived from Figure 3B of Figueroa and colleagues (<xref ref-type="bibr" rid="bib6">Figueroa et al., 2010</xref>).</p></list-item></list></p></list-item><list-item><p>Each experiment consists of five cohorts:<list list-type="bullet"><list-item><p>Cohort 1: 293T cells transfected with vector only</p></list-item><list-item><p>Cohort 2: 293T cells transfected with wild-type <italic>IDH1</italic></p></list-item><list-item><p>Cohort 3: 293T cells transfected with <italic>IDH1</italic><sup>R132H</sup></p></list-item><list-item><p>Cohort 4: 293T cells transfected with wild type <italic>IDH2</italic></p></list-item><list-item><p>Cohort 5: 293T cells transfected with <italic>IDH2</italic><sup>R172K</sup></p></list-item></list></p></list-item><list-item><p>Each cohort is then examined for methylation status by Western blot and levels of 2HG production by GC-MS.</p></list-item></list></sec><sec id="s2-1-2"><title>Materials and reagents</title><table-wrap position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Type</th><th>Manufacturer</th><th>Catalog #</th><th>Comments</th></tr></thead><tbody><tr><td>10 cm tissue culture dishes</td><td>Labware</td><td>Thermo Scientific</td><td>130182</td><td>Original unspecified</td></tr><tr><td>Bradford Assay Kit</td><td>Reporter assay</td><td>Bio-Rad</td><td>500-0201EDU</td><td>Original unspecified</td></tr><tr><td>DMEM</td><td>Cell culture</td><td>Corning</td><td>15013 CV</td><td>Replaces original from Invitrogen</td></tr><tr><td>Endo-free plasmid maxiprep kit</td><td>Kit</td><td>Qiagen</td><td>12362</td><td>Original unspecified</td></tr><tr><td>Fetal bovine serum (FBS)</td><td>Cell culture</td><td>CellGro</td><td>10437-028</td><td>Original cat # unspecified</td></tr><tr><td>293T cells</td><td>Cell line</td><td>ATCC</td><td>CRL-3216</td><td>Original source unspecified</td></tr><tr><td>HRP-conjugated donkey <break/>anti-rabbit secondary</td><td>Antibody</td><td>GE Healthcare</td><td>NA934V</td><td/></tr><tr><td>HRP-conjugated sheep <break/>anti-mouse secondary</td><td>Antibody</td><td>GE Healthcare</td><td>NA931V</td><td/></tr><tr><td><italic>IDH1</italic> ORF clone</td><td>Nucleic acid</td><td>OriGene</td><td>RC210582</td><td>Replaces ATCC plasmid <break/>in pCMV-Sport6</td></tr><tr><td><italic>IDH1</italic><sup>R132H</sup> ORF clone</td><td>Nucleic acid</td><td>OriGene</td><td>RC400096</td><td>Original generated <break/>by authors</td></tr><tr><td><italic>IDH2</italic> ORF clone</td><td>Nucleic acid</td><td>OriGene</td><td>RC201152</td><td>Replaces Invitrogen <break/>plasmid in pOTB7</td></tr><tr><td><italic>IDH2</italic><sup>R172K</sup> ORF clone</td><td>Nucleic acid</td><td>OriGene</td><td>RC400103</td><td>Original generated <break/>by authors</td></tr><tr><td>Mouse IgG1 monoclonal <break/>anti-IDH2</td><td>Antibody</td><td>Abcam</td><td>Ab55271</td><td/></tr><tr><td>Nitrocellulose <break/>membrane</td><td>Western blot reagent</td><td>Life Technologies</td><td>LC2006</td><td>Original source unspecified</td></tr><tr><td>Nonfat milk</td><td>Western blot reagent</td><td>Carnation</td><td/><td>Original source unspecified</td></tr><tr><td>NuPAGE 4-12% precast <break/>gradient gel</td><td>Western blot reagent</td><td>Invitrogen</td><td>WG1401BOX</td><td>Original source unspecified</td></tr><tr><td>Pierce™ ECL Plus <break/>Western Blotting Substrate</td><td>Western blot reagent</td><td>Life Technologies</td><td>32132</td><td>Original unspecified</td></tr><tr><td>pLPC vector plasmid <break/>(pLPC H-Ras V12)</td><td>Nucleic acid</td><td>Addgene</td><td>18741</td><td>Original source unspecified</td></tr><tr><td>Ponceau stain</td><td>Chemical</td><td>SIGMA</td><td>P7170-1L</td><td>Original unspecified</td></tr><tr><td>Protease Inhibitor <break/>Cocktail,</td><td>Inhibitor</td><td>Sigma-Aldrich</td><td>P8340</td><td>Original unspecified</td></tr><tr><td>Rabbit IgG monoclonal <break/>anti-H3</td><td>Antibody</td><td>Cell Signaling Technology</td><td>4499</td><td/></tr><tr><td>Rabbit monoclonal <break/>anti-H3K4me3</td><td>Antibody</td><td>Millipore</td><td>17-614</td><td/></tr><tr><td>Rabbit polyclonal <break/>anti-H3K36me3</td><td>Antibody</td><td>Abcam</td><td>Ab9050</td><td/></tr><tr><td>Rabbit polyclonal <break/>anti-H3K79me2</td><td>Antibody</td><td>Cell Signaling Technology</td><td>9757</td><td/></tr><tr><td>Rabbit polyclonal <break/>anti-H3K9me2</td><td>Antibody</td><td>Cell Signaling Technology</td><td>9753</td><td/></tr><tr><td>Rabbit polyclonal <break/>anti-H3K9me3</td><td>Antibody</td><td>Abcam</td><td>Ab8898</td><td/></tr><tr><td>Rabbit polyclonal <break/>anti-IDH1</td><td>Antibody</td><td>ProteinTech</td><td>12332-1-AP</td><td/></tr><tr><td>TBS + Tween 20</td><td>Buffer</td><td>Fisher Scientific</td><td>BP-2471-1</td><td>Original source unspecified</td></tr><tr><td>XCell II blot module</td><td>Instrument</td><td>Life Technologies</td><td>EI9051</td><td>Original unspecified</td></tr><tr><td>Acetonitrile, HPLC <break/>grade</td><td>Chemical</td><td>Spectrum</td><td>HP412</td><td>Original source unspecified</td></tr><tr><td>Chloroform</td><td>Chemical</td><td>Fisher</td><td>C606-4</td><td>Original unspecified</td></tr><tr><td>D-alpha-hydroxyglutaric <break/>acid disodium salt (2HG)</td><td>Chemical</td><td>Santa Cruz Biotechnology</td><td>Sc-227739</td><td>Replaces original from Sigma</td></tr><tr><td>Methanol, HPLC grade</td><td>Chemical</td><td>MP</td><td>300141</td><td>Original source unspecified</td></tr><tr><td>N-methyl-N-tert-butyldimethylsilyl <break/>trifluoroacetamide (MTBSTFA)</td><td>Chemical</td><td>Soltec Ventures</td><td>GC102</td><td>Replaces original <break/>from Regis</td></tr><tr><td>Norvaline</td><td>Chemical</td><td>Sigma</td><td>N7627</td><td>Original unspecified</td></tr><tr><td>Protein Concentration <break/>Assay; Quick Start <break/>Bradford Assay</td><td>Reporter assay</td><td>Bio-Rad</td><td>500-0205</td><td>Original unspecified</td></tr><tr><td>Lipofectamine 2000</td><td>Cell culture</td><td>Life Technologies</td><td>11668027</td><td>Original cat # unspecified</td></tr></tbody></table></table-wrap></sec><sec id="s2-1-3"><title>Procedure</title><p>Note: 293T cells are maintained in DMEM with 10% FBS at 37°C/5% CO<sub>2 </sub>All cells will be sent for STR profiling and mycoplasma testing.</p><list list-type="bullet"><list-item><p>Using the pLPC backbone and the OriGene ORF clones, clone in the sequences for wild-type <italic>IDH1</italic>, wild-type <italic>IDH2, IDH1</italic><sup>R132H</sup> or <italic>IDH2</italic><sup>R172K</sup> to generate the following vectors:<list list-type="order"><list-item><p>pLPC-<italic>IDH1</italic></p></list-item><list-item><p>pLPC-<italic>IDH2</italic></p></list-item><list-item><p>pLPC-<italic>IDH1</italic><sup>R132H</sup></p></list-item><list-item><p>pLPC-<italic>IDH2</italic><sup>R172K</sup></p></list-item></list></p></list-item><list-item><p>Prep each vector using an endo-free maxiprep kit according to the manufacturer’s instructions.</p></list-item><list-item><p>Confirm plasmid identity by sequencing insert and vector integrity by agarose gel electrophoresis.<list list-type="order"><list-item><p>Note; OriGene ORF clones are shipped with sequencing primers.</p></list-item></list></p></list-item><list-item><p>Plate 293T cells in <sup>#</sup>10 cm tissue culture dishes and let adhere overnight.<list list-type="order"><list-item><p>Plate two plates; one will be harvested for Western blot (Step 3), the other for metabolite analysis (Step 4).</p></list-item></list></p></list-item><list-item><p>Transfect 293T cells with appropriate plasmids with Lipofectamine 2000 according to the manufacturer’s instructions.<list list-type="order"><list-item><p>Note: Prepare separate transfection mixtures for each replicate, then use the same mixture for all plates within that replicate; do not use a single large volume for transfection mixture for all replicates.<list list-type="alpha-lower"><list-item><p>pLPC (empty vector)</p></list-item><list-item><p>pLPC-<italic>IDH1</italic></p></list-item><list-item><p>pLPC-<italic>IDH2</italic></p></list-item><list-item><p>pLPC-<italic>IDH1</italic><sup>R132H</sup></p></list-item><list-item><p>pLPC-<italic>IDH2</italic><sup>R172K</sup></p></list-item></list></p></list-item><list-item><p>Incubate for 3 days.<list list-type="alpha-lower"><list-item><p>At this point, the matched plates for each replicate will be harvested; one plate for Western blot analysis (Step 6), the matched plate for GC-MS analysis (Step 7).</p></list-item></list></p></list-item><list-item><p>Note; from this point forward, the analysis of each replicate must be conducted separately and independently from the other replicates. For example, each replicate should be run on its own gels.</p></list-item></list></p></list-item><list-item><p>Western blot analysis of methylation status:<list list-type="order"><list-item><p>Acid extraction of histones:<list list-type="alpha-lower"><list-item><p>Lyse cells in hypotonic lysis buffer for 1.<list list-type="roman-lower"><list-item><p>Hypotonic lysis buffer: 10mM HEPES, 10mM KCl, 1.5mM MgCl<sub>2</sub>, 0.5mM DTT, <sup>#</sup>protease inhibitor cocktail</p></list-item></list></p></list-item><list-item><p>Add H<sub>2</sub>SO<sub>4</sub> to 0.2N and incubate at 4°C overnight with rotation.</p></list-item><list-item><p><sup>#</sup>Centrifuge samples at 6,500x<italic>g</italic> for 10min at 4°C to pellet debris.</p></list-item><list-item><p>Precipitate proteins with 33% TCA.</p></list-item><list-item><p>Wash with acetone.</p></list-item><list-item><p>Resuspend in de-ionized water.</p></list-item></list></p></list-item><list-item><p><sup>*#</sup>Quantify protein concentration using a Bradford Assay.</p></list-item><list-item><p><sup>#</sup>Load ~ 50 µg of protein per well and separate proteins on a 10% NuPAGE 4-12% gradient gel.</p></list-item><list-item><p><sup>#</sup>Transfer to nitrocellulose membrane using an XCell II blot module at 25 V for 1-2 hr (start at 100 mA per gel).</p></list-item><list-item><p>*Perform a Ponceau stain and image to confirm transfer of proteins.<list list-type="alpha-lower"><list-item><p>Wash out Ponceau.</p></list-item></list></p></list-item><list-item><p>Block membrane for <sup>#</sup>1 hr in 5% non-fat milk in PBS with 0.5% Tween-20.</p></list-item><list-item><p>Incubate with primary antibodies <sup>#</sup>diluted in TBST + 1% nonfat milk at 4°C overnight. <sup>*</sup>Use the manufacturer’s recommended dilution.<list list-type="alpha-lower"><list-item><p>Anti-IDH1</p></list-item><list-item><p>Anti-IDH2</p></list-item><list-item><p>Anti-H3K4me3</p></list-item><list-item><p>Anti-H3K9me2</p></list-item><list-item><p>Anti-H3K9me3</p></list-item><list-item><p>Anti-H3K36me3</p></list-item><list-item><p>Anti-H3K79me2</p></list-item><list-item><p>Anti-H3 (loading control)<list list-type="roman-lower"><list-item><p><sup>#</sup>Each antibody will have its own gel run. Membranes will not be stripped and reprobed.</p></list-item></list></p></list-item></list></p></list-item><list-item><p>Wash membrane <sup>#</sup>twice with TBST for a total of 20 min.<list list-type="alpha-lower"><list-item><p>Incubate with HRP-conjugated secondary antibodies <sup>#</sup>diluted in TBST for 1 hr at room temperature. <sup>#*</sup>Use manufacturer recommended dilutions.</p></list-item></list></p></list-item><list-item><p>Wash three times with TBST.</p></list-item><list-item><p>Detect signal <sup>#</sup>using ECL plus according to the manufacturer’s instructions.</p></list-item><list-item><p>Quantify band intensities with ImageJ.<list list-type="alpha-lower"><list-item><p>Normalize methylation band intensities to total H3.</p></list-item><list-item><p>Divide normalized band intensities by the vector control band intensity.</p></list-item></list></p></list-item></list></p></list-item><list-item><p>Gas chromatography-mass spectrometry analysis of 2HG levels. Note; the data in the original paper and the methodology are derived from Figueroa and colleagues (<xref ref-type="bibr" rid="bib6">Figueroa et al., 2010</xref>).<list list-type="order"><list-item><p>Gently remove culture medium from cells 3 days after transfection, <sup>#</sup>wash cells quickly three times with 2 ml ice-cold PBS, and add <sup>#</sup>0.5 ml ice-cold 80% methanol containing 20 µM L-norvaline per well of a 6-well plate to the cells.<list list-type="alpha-lower"><list-item><p><sup>#</sup>Quantify protein concentration using the <sup>#</sup>Bio-Rad Quick Start Bradford Assay.</p></list-item></list></p></list-item><list-item><p>Incubate 20 min at -80°C.</p></list-item><list-item><p>Centrifuge at 14000x<italic>g</italic> for 20 min at 4°C.<list list-type="alpha-lower"><list-item><p><sup>#</sup>Counter-extract samples with chloroform to remove nonpolar metabolites.</p></list-item></list></p></list-item><list-item><p>Collect supernatant and dry using a <sup>#</sup>MiVac.</p></list-item><list-item><p>Redissolve dried extracts in <sup>#</sup>60 µL of a 1:1 mixture of acetonitrile and N-methyl-N-tert-butyldimethylsilyltrifluoroacetamide (MTBSTFA).</p></list-item><list-item><p>Heat the samples for 75 min at 70°C.</p></list-item><list-item><p>GC-MS analysis:<list list-type="alpha-lower"><list-item><p><sup>#</sup>A Shimadzu QP2010 Plus GC-MS is programmed with an injection temperature of 250°C, injection split ratio 1/10, with injection volume 0.3-1 µl. GC oven temperature starts at 130°C for 4 min, rising to 243°C at 6°C/min and to 280°C at 60°C/min with a final hold at this temperature for 2 min. GC flow rate with helium carrier gas was 50 cm/s. The GC column used is a 15 m x 0.25 mm x 0.25 µm Rxi-5ms (Restek). GC-MS interface temperature is 300°C and (electron impact) ion source temperature is 200°C, with 70 V/ 70 µA ionization voltage/ current. The mass spectrometer is set to scan m/z range 150-600, with ~1 kV detector sensitivity (modified as necessary).</p></list-item></list></p></list-item><list-item><p><sup>*#</sup>In parallel to the sample, run a standard curve of known amounts of 2HG.</p></list-item><list-item><p>Confirm and <sup>*#</sup>quantify 2HG metabolite peak using standard curve.</p></list-item><list-item><p>Analyze and <sup>*#</sup>quantify 2HG and glutamate signal (identified by elution time and mass fragment pattern) intensities by integration of peak areas.</p></list-item></list></p></list-item><list-item><p>Repeat independently from Step 4 onwards an additional five times.</p></list-item></list></sec><sec id="s2-1-4"><title>Deliverables</title><list list-type="bullet"><list-item><p>Data to be collected:<list list-type="bullet"><list-item><p>Sequence files and agarose gel images confirming vector identity</p></list-item><list-item><p>Full gel images of western blots with ladder (as seen in Figure 1B)<list list-type="bullet"><list-item><p>Images of Ponceau stained membranes</p></list-item></list></p></list-item><list-item><p>Quantification of band intensities (as seen in Supplemental Figure 1A)</p></list-item><list-item><p>GC-MS data</p></list-item><list-item><p>Quantification of signal intensities of 2HG and glutamate (as seen in Figure 1B)</p></list-item></list></p></list-item></list></sec><sec id="s2-1-5"><title>Confirmatory analysis plan</title><list list-type="bullet"><list-item><p>Statistical Analysis of the Replication Data: Note: At the time of analysis we will calculate Pearson’s <italic>r</italic> to check for correlation between the six dependent variables, normalized intensities measured for each of the histone lysine methylations, for the Western blot data. We will also perform the Shapiro-Wilk test and generate a quantile-quantile plot to assess the normality of the Western blot data and 2HG/glutamate ratios. We will also perform Levene’s test to assess homoscedasticity. If the data appear skewed we will perform a log transformation in order to proceed with the proposed statistical analysis. If the log transformation does not result in similar variance across groups, we will perform the equivalent non-parametric test listed in Power Calculations for this protocol.<list list-type="bullet"><list-item><p>Western blot:<list list-type="bullet"><list-item><p>MANOVA (six dependent variables are the normalized intensities for each of the histone lysine methylations; four independent variables are the IDH1 and IDH2 variants (all normalized to vector) with the following planned comparisons using Bonferroni’s correction:<list list-type="bullet"><list-item><p>Wild-type IDH1 compared to IDH1<sup>R132H</sup>, for H3K9me2.</p></list-item><list-item><p>Wild-type IDH2 compared to IDH2<sup>R172K</sup>, for H3K9me2.</p></list-item></list></p></list-item></list></p></list-item><list-item><p>2HG/glutamate ratios:<list list-type="bullet"><list-item><p>One-way ANOVA (one dependent variable is the 2HG/glutamate ratio; four independent variables are the IDH1 and IDH2 variants) with the following planned comparisons using Bonferroni’s correction:<list list-type="bullet"><list-item><p>IDH1<sup>WT</sup> compared to IDH1<sup>R132H</sup></p></list-item><list-item><p>IDH2<sup>WT</sup> compared to IDH2<sup>R172K</sup></p></list-item></list></p></list-item></list></p></list-item></list></p></list-item><list-item><p>Meta-analysis of original and replication attempt effect sizes:<list list-type="bullet"><list-item><p>For Western blot:<list list-type="bullet"><list-item><p>The replication attempt will perform the statistical analysis listed above, compute the effects sizes, compare them against the reported effect size in the original paper and use a meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot.</p></list-item></list></p></list-item><list-item><p>For 2HG/glutamate ratios:<list list-type="bullet"><list-item><p>The replication data will be presented as a mean with 95% confidence intervals and will include the original data point, calculated directly from the representative image, as a single point on the same plot for comparison.</p></list-item></list></p></list-item></list></p></list-item><list-item><p>Additional exploratory analysis:<list list-type="bullet"><list-item><p>Correlation analysis (Pearson’s <italic>r</italic>) of each of the six relative histone methylation levels to 2HG/glutamate levels using Bonferroni ‘s correction (as seen in Supplemental Figure 1B).</p></list-item></list></p></list-item></list></sec><sec id="s2-1-6"><title>Known differences from the original study</title><list list-type="bullet"><list-item><p>The replication attempt will quantify total amounts of 2HG in addition to the ratio of 2HG to glutamate.</p></list-item><list-item><p>Aspects of the Western blot protocol are provided by the replicating lab; complete details of the original protocol were unavailable.</p></list-item></list></sec><sec id="s2-1-7"><title>Provisions for quality control</title><p>All data obtained from the experiment - raw data, data analysis, control data and quality control data - will be made publicly available, either in the published manuscript or as an open access dataset available on the Open Science Framework (<ext-link ext-link-type="uri" xlink:href="https://osf.io/vfsbo/">https://osf.io/vfsbo/</ext-link>).</p><list list-type="bullet"><list-item><p>Sequence files and agarose gel images confirming vector identity and integrity</p></list-item><list-item><p>Ponceau stains confirming protein transfer to membranes</p></list-item><list-item><p>STR profiling and mycoplasma testing results</p></list-item></list></sec></sec><sec id="s2-2"><title>Protocol 2: Examining the effects of mutations in IDH2 on differentiation of 3T3-L1 cells</title><p>This protocol describes how to induce the differentiation of 3T3-L1 cells into adipocytes, which involves extensive chromatin remodeling, after transfection with wild type and mutant forms of <italic>IDH2</italic> and assess the level of differentiation by Oil-Red-O staining, as seen in Figure 2A and B, and adipocyte marker expression, as seen in Figure 2D.</p><sec id="s2-2-1"><title>Sampling</title><list list-type="bullet"><list-item><p>This experiment will use 5 biological replicates for a minimum power of 80%. The metabolite data is qualitative, thus to determine an appropriate number of replicates to initially perform, sample sizes based on a range of potential variance was determined.<list list-type="bullet"><list-item><p>See Power Calculations for details.</p></list-item></list></p></list-item><list-item><p>Each experiment will consist of three cohorts:<list list-type="bullet"><list-item><p>Cohort 1: 3T3-L1 cells transduced with vector</p></list-item><list-item><p>Cohort 2: 3T3-L1 cells transduced with wild-type <italic>IDH2</italic></p></list-item><list-item><p>Cohort 3: 3T3-L1 cells transduced with <italic>IDH2</italic><sup>R172K</sup></p></list-item></list></p></list-item><list-item><p>Each cohort will have 5 plates per biological replicate:<list list-type="bullet"><list-item><p>One plate will be used to assess IDH2 expression by Western blot.</p></list-item><list-item><p>The second plate will be used to assess intracellular levels of 2HG.</p></list-item><list-item><p>The third plate will be assessed for adipogenesis by Oil-Red-O staining.</p></list-item><list-item><p>The fourth and fifth plates will have mRNA harvested for qRT-PCR analysis.</p></list-item></list></p></list-item></list></sec><sec id="s2-2-2"><title>Materials and reagents</title><table-wrap position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Type</th><th>Manufacturer</th><th>Catalog #</th><th>Comments</th></tr></thead><tbody><tr><td>Isobutylmethylxanthine</td><td>Inhibitor</td><td>Sigma</td><td>I5879</td><td>Original cat# unspecified</td></tr><tr><td>Dexamethasone</td><td>Chemical</td><td>Sigma</td><td>D4902</td><td>Original cat# unspecified</td></tr><tr><td>Insulin</td><td>Growth factor</td><td>Sigma</td><td>I3536</td><td>Original cat# unspecified</td></tr><tr><td>Troglitazone</td><td>Chemical</td><td>Sigma</td><td>T2573</td><td>Original cat# unspecified</td></tr><tr><td>pCL-Eco helper plasmid</td><td>Nucleic acid</td><td>Addgene</td><td>12371</td><td>Original source unspecified</td></tr><tr><td>293T cells</td><td>Cell line</td><td>ATCC</td><td>CRL-3216</td><td>Original source unspecified</td></tr><tr><td>3T3-L1 cells</td><td>Cell line</td><td>ATCC</td><td>CL-173</td><td>Original source unspecified</td></tr><tr><td>Puromycin</td><td>Chemical</td><td>Life Technologies</td><td>A11138-02</td><td>Original unspecified</td></tr><tr><td>RIPA buffer</td><td>Cell culture</td><td>Millipore</td><td>20188</td><td>Original source unspecified</td></tr><tr><td>Nitrocellulose membrane</td><td>Western blot reagent</td><td>Life Technologies</td><td>LC2006</td><td>Original source unspecified</td></tr><tr><td>Ponceau stain</td><td>Chemical</td><td>Sigma</td><td>P7170</td><td>Original source unspecified</td></tr><tr><td>Rabbit polyclonal anti-IDH1</td><td>Antibody</td><td>ProteinTech</td><td>12332-1-AP</td><td/></tr><tr><td>Mouse IgG1 monoclonal anti-IDH2</td><td>Antibody</td><td>Abcam</td><td>Ab55271</td><td/></tr><tr><td>HRP-conjugated donkey anti-rabbit secondary</td><td>Antibody</td><td>GE Healthcare</td><td>NA934V</td><td/></tr><tr><td>HRP-conjugated sheep anti-mouse secondary</td><td>Antibody</td><td>GE Healthcare</td><td>NA931V</td><td/></tr><tr><td>Oil-Red-O</td><td>Chemical</td><td>Sigma</td><td>O1391</td><td>Original source unspecified</td></tr><tr><td>paraformaldehyde</td><td>Chemical</td><td>Tousimis</td><td>1008A</td><td>Original source unspecified</td></tr><tr><td>6-well tissue culture plates</td><td>Labware</td><td>Sarstedt</td><td>83.1839</td><td>Original unspecified</td></tr><tr><td>XtremeGene HP reagent</td><td>Cell culture</td><td>Roche</td><td>06366244001</td><td>Original unspecified</td></tr><tr><td>DMEM</td><td>Cell culture</td><td>Corning</td><td>15013 CV</td><td>Replaces original from Invitrogen</td></tr><tr><td>FBS</td><td>Cell culture</td><td>CellGro</td><td>10437-028</td><td>Original cat # unspecified</td></tr><tr><td>OPTI-MEM</td><td>Cell culture</td><td>Life Technologies</td><td>31986070</td><td>Original unspecified</td></tr><tr><td>0.45 µm low binding syringe filter</td><td>Labware</td><td>Millipore</td><td>SLHV013SL</td><td>Original unspecified</td></tr><tr><td>Endo-free maxiprep kit</td><td>Kit</td><td>Qiagen</td><td>12362</td><td>Original unspecified</td></tr><tr><td>Protein Concentration Assay; Quick Start Bradford Assay</td><td>Reporter assay</td><td>Bio-Rad</td><td>500-0205</td><td>Original unspecified</td></tr><tr><td>Spectrophotometer</td><td>Instrument</td><td>Beckman Coulter</td><td>DU800</td><td>Original unspecified</td></tr><tr><td>TRIzol</td><td>Chemical</td><td>Invitrogen</td><td>15596-018</td><td>Original cat# unspecified</td></tr><tr><td>SuperScript II reverse transcriptase</td><td>Kit</td><td>Invitrogen</td><td>18064-014</td><td>Original cat# unspecified</td></tr><tr><td>7900HT Sequence Detection System</td><td>Instrument</td><td>Applied Biosystems</td><td/><td/></tr><tr><td>Pparg Taqman assays; Hs00234592_m1</td><td>Nucleic acid</td><td>Applied Biosystems</td><td>Cat. # 4351372</td><td>Original assay unspecified</td></tr><tr><td>Cebpa Taqman assays; Hs00269972_s1</td><td>Nucleic acid</td><td>Applied Biosystems</td><td>Cat. # 4331182</td><td>Original assay unspecified</td></tr><tr><td>Adipoq Taqman assays; Hs00605917_m1</td><td>Nucleic acid</td><td>Applied Biosystems</td><td>Cat. # 4331182</td><td>Original assay unspecified</td></tr><tr><td>18S rRNA Taqman assays; Hs99999901_s1</td><td>Nucleic acid</td><td>Applied Biosystems</td><td>Cat. # 4331182</td><td>Original assay unspecified</td></tr></tbody></table></table-wrap></sec><sec id="s2-2-3"><title>Procedure</title><p>Note: 3T3-L1 and 293T cells are maintained in DMEM with 10% FBS at 37°C/5% CO<sub>2 .</sub>All cells will be sent for STR profiling and mycoplasma testing. pLPC (empty vector), pLPC-<italic>IDH2</italic>, and pLPC-<italic>IDH2</italic><sup>R172K</sup> are generated in Protocol 1.</p><list list-type="bullet"><list-item><p>Generate vector and <italic>IDH2</italic> wild type and mutant expressing retroviruses.<list list-type="order"><list-item><p><sup>#</sup>Transfect 293T cells with pCL-Eco helper plasmid and vector or <italic>IDH2</italic> vectors.<list list-type="alpha-lower"><list-item><p>Spot virus construct in 6 well plates at 1000 ng/well.</p></list-item><list-item><p>Perform X-tremeGeneHP reverse transfection as follows:<list list-type="roman-lower"><list-item><p>Make the helper plasmid mix; 700 ng/well.</p></list-item><list-item><p>Add 4 µL of XtremeGene HP to 400 µL OPTI-MEM.<list list-type="bullet"><list-item><p>Mix by light tapping.</p></list-item></list></p></list-item><list-item><p>Mix together the helper plasmids with the XtremeGeneHP reagent and OPTI-MEM.</p></list-item><list-item><p>Add 400 µL of the mix to each well and incubate for at least 30 min at room temperature.</p></list-item><list-item><p>Meanwhile, resuspend 293T cells in DMEM + 10% FBS at 1.2x10<sup>6</sup> cells/ml.</p></list-item><list-item><p>Add 1600 µL of cells to each well.</p></list-item></list></p></list-item></list></p></list-item><list-item><p><sup>#</sup>24 hr later, replace media (2 ml total).</p></list-item><list-item><p><sup>#</sup>48 hr post transfection, collect supernatant from each well.<list list-type="alpha-lower"><list-item><p>Centrifuge at 500x<italic>g</italic> for 10 min at room temperature to pellet debris.</p></list-item><list-item><p>Filter supernatant through a 0.45 µm syringe filter, aliquot and store at -80°C.</p></list-item></list></p></list-item></list></p></list-item><list-item><p>Transduce 3T3-L1 cells with viral supernatant.<list list-type="order"><list-item><p><sup>#</sup>Seed cells in 6-well plates and incubate overnight.<list list-type="alpha-lower"><list-item><p>Cells should be 50-60% confluent the next day.</p></list-item></list></p></list-item><list-item><p><sup>#</sup>Add viral supernatant to medium.<list list-type="alpha-lower"><list-item><p>Supernatant will be added at varying concentrations to determine optimal transduction efficiency; 1:5 to 1:10 – 150 to 300 µL per well.</p></list-item></list></p></list-item><list-item><p><sup>#</sup>Adjust media volume to 1.4 ml per well.</p></list-item><list-item><p><sup>#</sup>Add polybrene in 100 µL of media into each well for a final concentration of 8 µg/ml.</p></list-item><list-item><p><sup>#</sup>Spinoculate by spinning at 1000x<italic>g</italic> for 60 min at room temperature.<list list-type="alpha-lower"><list-item><p>Incubate overnight.</p></list-item></list></p></list-item><list-item><p><sup>#</sup>Change media to remove viral transduction media.<list list-type="alpha-lower"><list-item><p>Replace with fresh media.</p></list-item></list></p></list-item><list-item><p>Grow cells with 2.5 µg/ml puromycin for 7 days to select for stable expression of either wild-type or mutant <italic>IDH2</italic>.<list list-type="alpha-lower"><list-item><p>Maintain cells in puromycin.</p></list-item><list-item><p>Also treat a non-transduced well of 3T3-L1 cells as a control showing susceptibility to puromycin.</p></list-item><list-item><p>Split each biological replicate into 5 plates for the four assays being performed.<list list-type="roman-lower"><list-item><p>Plate 1 is for Western blot</p></list-item><list-item><p>Plate 2 is for GC-MS</p></list-item><list-item><p>Plate 3 is for Oil-Red-O staining (harvested 7 days after differentiation)</p></list-item><list-item><p>Plate 4 and 5 are for qRT-PCR (harvested 0 and 4 days after differentiation)</p></list-item></list></p></list-item></list></p></list-item></list></p></list-item><list-item><p>Generate whole cell lysates from the first plate of each cohort:<list list-type="order"><list-item><p>Lyse cells and sonicate in RIPA buffer.<list list-type="alpha-lower"><list-item><p>RIPA buffer: 1% sodium deoxycholate, 0.1% SDS, 1% Triton X-100, 0.01 M Tris pH 8.0 and 0.14 M NaCl</p></list-item><list-item><p><sup>#</sup>Sonicate for 1 min, at 180 watts with rounds of 10 sec on/10 sec off. Keep sample on ice during sonication.</p></list-item></list></p></list-item><list-item><p>Centrifuge lysates at 14000x<italic>g</italic> for 10 min at 4°C.</p></list-item><list-item><p>Collect supernatant and measure total protein concentration <sup>#</sup>using a Bradford assay.</p></list-item><list-item><p>Perform Western blot as outlined in Protocol 1 Step 6 using the following primary antibodies <sup>*</sup>at the manufacturer’s recommended dilution:<list list-type="alpha-lower"><list-item><p>Anti-IDH1</p></list-item><list-item><p>Anti-IDH2</p></list-item></list></p></list-item></list></p></list-item><list-item><p>Harvest the second plate for metabolite analysis by mass spectrometry as described in Protocol 1 Step 4.</p></list-item><list-item><p>Induce 3T3-L1 cells to differentiate into adipocytes.<list list-type="order"><list-item><p>Incubate cells for 2 days with a differentiation cocktail composed of 0.5 mM isobutylmethylxanthine, 1 mM dexamethasone, 5 mg/ml insulin and 5 mM troglitazone supplementing the standard media.</p></list-item><list-item><p>After 3 days, maintain cells with 5 mg/ml insulin until harvested.</p></list-item></list></p></list-item><list-item><p>After 7 days of differentiation, assess adipogenesis by Oil-Red-O staining in the third plate from each cohort.<list list-type="order"><list-item><p>Wash cells in PBS and fix in 3% paraformaldehyde for 20 min at room temperature.</p></list-item><list-item><p>Wash cells with de-ionized water.</p></list-item><list-item><p>Stain with Oil-Red-O solution according to the manufacturer’s protocol.</p></list-item><list-item><p>Image stained wells by brightfield microscopy and <sup>*</sup>quantify Oil-Red-O staining by extracting oil-red-o in isopropanol and reading absorbance at 500 nm.</p></list-item></list></p></list-item><list-item><p>Harvest fourth plate for RNA extraction at Day 0 of differentiation and the fifth plate at Day 4 of differentiation and perform qRT-PCR to assess expression levels of adipocyte markers at each time point.<list list-type="order"><list-item><p>Harvest cells and extract RNA using TRIzol according to the manufacturer’s instructions.</p></list-item><list-item><p>Reverse transcribe RNA and synthesize cDNA using SuperScript II reverse transcriptase according to the manufacturer’s protocol.<list list-type="alpha-lower"><list-item><p>Assess purity and concentration of RNA and cDNA spectrophotometrically; record A<sub>260</sub>/A<sub>280</sub> and A<sub>260</sub>/A<sub>230</sub> ratios.</p></list-item></list></p></list-item><list-item><p>Perform qPCR on a 7900HT Sequence Detection system using Taqman gene expression assays for the following genes:<list list-type="alpha-lower"><list-item><p>Pparg</p></list-item><list-item><p>Cebpa</p></list-item><list-item><p>Adipoq</p></list-item><list-item><p>18S rRNA for normalization.<list list-type="roman-lower"><list-item><p><sup>*</sup>Primers sequences and PCR cycling conditions will be optimized.</p></list-item></list></p></list-item></list></p></list-item></list></p></list-item><list-item><p>Repeat independently from Step 2 onwards an additional four times.</p></list-item></list></sec><sec id="s2-2-4"><title>Deliverables</title><list list-type="bullet"><list-item><p>Data to be collected:<list list-type="bullet"><list-item><p>Whole gel images of Western blots with ladder (as seen in Figure 2A)</p></list-item><list-item><p><sup>*</sup>Densitometric quantification of bands<list list-type="bullet"><list-item><p>Also normalized to the loading control.</p></list-item></list></p></list-item><list-item><p>Images of wells stained with Oil-Red-O (as seen in Figure 2B)</p></list-item><list-item><p><sup>*</sup>Quantification of Oil-Red-O levels for each cohort</p></list-item><list-item><p>All raw qRT-PCR data</p></list-item><list-item><p>Graph of gene expression over time for each of the three adipocyte markers (as seen in Figure 2D)</p></list-item></list></p></list-item></list></sec><sec id="s2-2-5"><title>Confirmatory analysis plan</title><list list-type="bullet"><list-item><p>Statistical Analysis of the Replication Data: Note: At the time of analysis we will calculate Pearson’s <italic>r</italic> to check for correlation between the three dependent variables, normalized gene expression for each of the adipocyte markers, for the qRT-PCR data. We will also perform the Shapiro-Wilk test and generate a quantile-quantile plot to assess the normality of the qRT-PCR data and 2HG/glutamate ratios. We will also perform Levene’s test to assess homoscedasticity. If the data appears skewed we will perform a log transformation in order to proceed with the proposed statistical analysis. If this is not possible we will perform the equivalent non-parametric test listed in Power Calculations for this protocol.<list list-type="bullet"><list-item><p>Western Blot:<list list-type="bullet"><list-item><p>Confirmatory; no analysis performed</p></list-item></list></p></list-item><list-item><p>2HG/glutamate ratio:<list list-type="bullet"><list-item><p>One-way ANOVA (one dependent variable is the 2HG/glutamate ratio; three independent variables are the vector and <italic>IDH2</italic> variants) with the following planned comparison using Fisher’s LSD correction:<list list-type="bullet"><list-item><p><italic>IDH2</italic><sup>R172K</sup>compared to <italic>IDH2</italic><sup>WT</sup></p></list-item></list></p></list-item></list></p></list-item><list-item><p>qRT-PCR:<list list-type="bullet"><list-item><p>One-way MANOVA (three dependent variables are the normalized gene expression of each of the adipocyte markers on day 4; three independent variables are the vector and IDH2 variants) with the following planned comparisons using Bonferroni’s correction:<list list-type="bullet"><list-item><p><italic>IDH2</italic><sup>R172</sup>compared to vector for each gene (three comparisons total)</p></list-item><list-item><p><italic>IDH2</italic><sup>R172K</sup>compared to <italic>IDH2</italic><sup>WT</sup> for each gene (three comparisons total)</p></list-item></list></p></list-item></list></p></list-item></list></p></list-item><list-item><p>Meta-analysis of original and replication attempt effect sizes:<list list-type="bullet"><list-item><p>For qRT-PCR:<list list-type="bullet"><list-item><p>The replication attempt will perform the statistical analysis listed above, compute the effects sizes, compare them against the reported effect size in the original paper and use a meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot.</p></list-item></list></p></list-item><list-item><p>For 2HG/glutamate ratios:<list list-type="bullet"><list-item><p>The replication data will be presented as a mean with 95% confidence intervals and will include the original data point, calculated directly from the representative image, as a single point on the same plot for comparison.</p></list-item></list></p></list-item></list></p></list-item><list-item><p>Additional exploratory analysis:<list list-type="bullet"><list-item><p>Oil-Red-O staining:<list list-type="bullet"><list-item><p>One-way ANOVA (one dependent variable is the A<sub>500</sub> readings; three independent variables are the vector and <italic>IDH2</italic> variants) with the following planned comparison using Fisher’s LSD correction:<list list-type="bullet"><list-item><p><italic>IDH2</italic><sup>R172K</sup> compared to <italic>IDH2</italic><sup>WT</sup></p></list-item></list></p></list-item></list></p></list-item></list></p></list-item></list></sec><sec id="s2-2-6"><title>Known differences from the original study</title><list list-type="bullet"><list-item><p>Aspects of the Western blot protocol are provided by the replicating lab; complete details of the original protocol were unavailable.</p></list-item><list-item><p>Aspects of the viral production protocol are adapted from the replicating lab’s in-house protocol.<list list-type="bullet"><list-item><p>Viral supernatant will be collected only at 48 hr post-transection and will not be combined with viral supernatant collected at 72 hr.</p></list-item></list></p></list-item><list-item><p>In addition to imaging Oil-Red-O stained plates, the replication attempt will quantify the amount of Oil-Red-O staining spectrophotometrically.</p></list-item></list></sec><sec id="s2-2-7"><title>Provisions for quality control</title><p>All data obtained from the experiment - raw data, data analysis, control data and quality control data - will be made publicly available, either in the published manuscript or as an open access dataset available on the Open Science Framework (<ext-link ext-link-type="uri" xlink:href="https://osf.io/vfsbo/">https://osf.io/vfsbo/</ext-link>).</p><list list-type="bullet"><list-item><p>Sequence files and agarose gel images confirming vector identity and integrity</p></list-item><list-item><p>Ponceau stains confirming protein transfer to membranes</p></list-item><list-item><p>STR profiling and mycoplasma testing results</p></list-item><list-item><p>Absorbance data for RNA and cDNA</p></list-item></list></sec></sec><sec id="s2-3"><title>Protocol 3: Assessing the role of KDM4C on differentiation of 3T3-L1 cells</title><p>This protocol describes how to treat 3T3-L1 cells with an siRNA against the histone demethylase KDM4C, whose activity is inhibited by 2HG, and assess the effect of loss of KDM4C activity on methylation and differentiation, as seen in Figure 4D and Supplemental Figure 8.</p><sec id="s2-3-1"><title>Sampling</title><list list-type="bullet"><list-item><p>This experiment will be repeated 3 times for a minimum power of 80%. The Western blot data is qualitative, thus to determine an appropriate number of replicates to initially perform, sample sizes based on a range of potential variance was determined.<list list-type="bullet"><list-item><p>See Power calculations for details.</p></list-item></list></p></list-item><list-item><p>Each experiment consists of five cohorts:<list list-type="bullet"><list-item><p>Cohort 1: 3T3-L1 cells treated with scramble control siRNAs</p></list-item><list-item><p>Cohort 2: 3T3-L1 cells treated with siRNAs #1 against KDM4C</p></list-item><list-item><p>Cohort 3: 3T3-L1 cells treated with siRNAs #2 against KDM4C</p></list-item><list-item><p>Cohort 4: 3T3-L1 cells treated with siRNAs #3 against KDM4C</p></list-item><list-item><p>Cohort 5: untreated 3T3-L1 cells [additional control]</p></list-item></list></p></list-item><list-item><p>Each cohort is induced to differentiate, followed by:<list list-type="bullet"><list-item><p>Assessment of methylation by Western blot for:<list list-type="bullet"><list-item><p>Anti-KDM4C</p></list-item><list-item><p>Anti-H3K9me3</p></list-item><list-item><p>Anti-H3</p></list-item><list-item><p>Anti-β-actin</p></list-item></list></p></list-item><list-item><p>Assessment of differentiation by Oil-Red-O staining</p></list-item></list></p></list-item></list></sec><sec id="s2-3-2"><title>Materials and reagents</title><table-wrap position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Type</th><th>Manufacturer</th><th>Catalog #</th><th>Comments</th></tr></thead><tbody><tr><td>3T3-L1 cells</td><td>Cell line</td><td>ATCC</td><td>CL-173</td><td>Original source unspecified</td></tr><tr><td>DMEM</td><td>Cell culture</td><td>Corning</td><td>15013 CV</td><td>Replaces original from Invitrogen</td></tr><tr><td>FBS</td><td>Cell culture</td><td>CellGro</td><td>10437-028</td><td>Original cat # unspecified</td></tr><tr><td>KDM4C siRNA #1</td><td>Nucleic acid</td><td colspan="3">Synthesis left to the discretion of the replicating lab</td></tr><tr><td>KDM4C siRNA #2</td><td>Nucleic acid</td><td colspan="3">Synthesis left to the discretion of the replicating lab</td></tr><tr><td>KDM4C siRNA #3</td><td>Nucleic acid</td><td colspan="3">Synthesis left to the discretion of the replicating lab</td></tr><tr><td>Scrambled control siRNA</td><td>Nucleic acid</td><td>Dharmacon</td><td>D-001810-01-20</td><td/></tr><tr><td>Lipofectamine RNAiMAX</td><td>Cell culture</td><td>Invitrogen</td><td>13778-030</td><td>Original cat# unspecified</td></tr><tr><td>isobutylmethylxanthine</td><td>Inhibitor</td><td>Sigma</td><td>I5879</td><td>Original cat# unspecified</td></tr><tr><td>dexamethasone</td><td>Chemical</td><td>Sigma</td><td>D4902</td><td>Original cat# unspecified</td></tr><tr><td>insulin</td><td>Growth factor</td><td>Sigma</td><td>I3536</td><td>Original cat# unspecified</td></tr><tr><td>Troglitazone</td><td>Chemical</td><td>Sigma</td><td>T2573</td><td>Original cat# unspecified</td></tr><tr><td>RIPA buffer</td><td>Cell culture</td><td>Millipore</td><td>20188</td><td>Original source unspecified</td></tr><tr><td>Nitrocellulose membrane</td><td>Western blot reagent</td><td>Life Technologies</td><td>LC2006</td><td>Original source unspecified</td></tr><tr><td>Ponceau stain</td><td>Chemical</td><td>Sigma</td><td>P7170</td><td>Original unspecified</td></tr><tr><td>Mouse IgG<sub>2a</sub> monoclonal anti-β-actin</td><td>Antibody</td><td>Sigma</td><td>A5316</td><td/></tr><tr><td>Rabbit IgG monoclonal anti-H3</td><td>Antibody</td><td>Cell Signaling Technology</td><td>4499</td><td/></tr><tr><td>Rabbit polyclonal anti-H3K9me3</td><td>Antibody</td><td>Abcam</td><td>Ab8898</td><td/></tr><tr><td>Rabbit polyclonal anti-KDM4C</td><td>Antibody</td><td>Abcam</td><td>Ab85454</td><td/></tr><tr><td>Oil-Red-O</td><td>Chemical</td><td>Sigma</td><td>O1391</td><td>Original source unspecified</td></tr><tr><td>paraformaldehyde</td><td>Chemical</td><td>Tousimis</td><td>1008A</td><td>Original source unspecified</td></tr></tbody></table></table-wrap></sec><sec id="s2-3-3"><title>Procedure</title><p>Note: 3T3-L1 cells are maintained in DMEM with 10% FBS at 37°C/5% CO<sub>2</sub>.<sub> </sub>All cells will be sent for STR profiling and mycoplasma testing.</p><list list-type="bullet"><list-item><p>Transfect with 3T3-L1 cells with siRNAs against KDM4C:<list list-type="order"><list-item><p>Plate out equal densities of single cell suspensions of 3T3-L1 cells in <sup>#</sup>6-well plates.<list list-type="alpha-lower"><list-item><p><sup>*</sup>Optimize the number of cells to plate per well.</p></list-item><list-item><p>Plate out two plates per siRNA pool (control vs. siKDM4C).<list list-type="roman-lower"><list-item><p>One will be harvested on Day 3 of differentiation for Western blot analysis.</p></list-item><list-item><p>One will be used on Day 7 of differentiation for Oil-Red-O analysis.</p></list-item></list></p></list-item></list></p></list-item><list-item><p>Transfect with the following siRNAs at a final concentration of 40 nM using Lipofectamine RNAiMAX according to the manufacturer’s instructions.<table-wrap id="tblu1" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">1</th><th>Sense</th><th>5’-GCUUGAAUCUCCCAAGAUATT-3’</th></tr><tr><th>Antisense</th><th>5’-UAUCUU GGGAGAUUCAAGCTT-3’</th></tr></thead><tbody><tr><td rowspan="2">2</td><td>Sense</td><td>5’-CAAAGUAUCUUGGAUCAAATT-3’</td></tr><tr><td>Antisense</td><td>5’-UUUGAUCCAAGAUACUUUGCC-3’</td></tr><tr><td rowspan="2">3</td><td>Sense</td><td>5’-GAGGAGUU UCGGGAGUUCAACAAAU-3’</td></tr><tr><td>Antisense</td><td>5’-AUUUGUUGAACUCCCGAA ACUCCUC-3’</td></tr></tbody></table></table-wrap><list list-type="alpha-lower"><list-item><p>Transfect control wells with a scrambled control siRNA.</p></list-item><list-item><p>Also plate control wells with no transfection.</p></list-item></list></p></list-item><list-item><p>Incubate for 3 days.</p></list-item></list></p></list-item><list-item><p>Induce differentiation of control siRNA and antisense siRNA transduced 3T3-L1 cells as specified in Protocol 2 Step 6.</p></list-item><list-item><p>3 days after differentiation, harvest one plate from each treatment and prepare whole cell lysates as specified in Protocol 2 Step 7.</p></list-item><list-item><p>Perform Western blot analysis on all whole cell lysates from Day 3 as described in Protocol 2 Step 7.<list list-type="order"><list-item><p>Probe with:<list list-type="alpha-lower"><list-item><p>Anti-KDM4C</p></list-item><list-item><p>Anti-H3K9me3</p></list-item><list-item><p>Anti-H3</p></list-item><list-item><p>Anti-β-actin</p></list-item></list></p></list-item><list-item><p>Quantify band intensities with ImageJ.<list list-type="alpha-lower"><list-item><p>Normalize H3K9me3 band intensities to total H3.</p></list-item><list-item><p>Normalize KDM4C band intensities to ß-actin.</p></list-item></list></p></list-item></list></p></list-item><list-item><p>At Day 7 of differentiation, assess level of differentiation by Oil-Red-O staining as specified in Protocol 2 Step 8.<list list-type="order"><list-item><p>Image wells and quantify Oil-Red-O expression.</p></list-item></list></p></list-item><list-item><p>Repeat experiment an additional two times.</p></list-item></list></sec><sec id="s2-3-4"><title>Deliverables</title><list list-type="bullet"><list-item><p>Data to be collected:<list list-type="bullet"><list-item><p>Whole gel images of all Western blots with ladder (as seen in the top of Figure 4D)</p></list-item><list-item><p>Images of Oil-Red-O stained wells (as seen in the bottom half of Figure 4D)</p></list-item></list></p></list-item><list-item><p>Quantification of Oil-Red-O staining at Day 7 of differentiation (compare to Supplemental Figure 8B)</p></list-item></list></sec><sec id="s2-3-5"><title>Confirmatory analysis plan</title><list list-type="bullet"><list-item><p>Statistical Analysis of the Replication Data: Note: At the time of analysis we will calculate Pearson’s <italic>r</italic> to check for correlation between the two dependent variables, normalized intensities measured for KDM4C and H3K9me3, for the Western blot data. We will also perform the Shapiro-Wilk test and generate a quantile-quantile plot to assess the normality of the Western blot and Oil-Red-O data. We will also perform Levene’s test to assess homoscedasticity. If the data appears skewed we will perform a log transformation in order to proceed with the proposed statistical analysis. If this is not possible we will perform the equivalent non-parametric test listed in Power Calculations for this protocol.<list list-type="bullet"><list-item><p>Quantification of Oil-Red-O staining:<list list-type="bullet"><list-item><p>One way ANOVA (one dependent variable is the A<sub>500</sub> readings; four independent variables are the control and three KDM4C siRNA sequences) with the following planned comparisons using Bonferroni’s correction:<list list-type="bullet"><list-item><p>Control siRNA compared to KDM4C siRNA #1</p></list-item><list-item><p>Control siRNA compared to KDM4C siRNA #2</p></list-item><list-item><p>Control siRNA compared to KDM4C siRNA #3 [additional exploratory analysis]</p></list-item></list></p></list-item></list></p></list-item><list-item><p>Western blot:<list list-type="bullet"><list-item><p>One-way MANOVA (two dependent variables are the normalized intensities measured for KDM4C and H3K9me3; four independent variables are the control and three KDM4C siRNA sequences) with the following planned comparisons using Bonferroni’s correction:<list list-type="bullet"><list-item><p>H3K9me3 levels:<list list-type="bullet"><list-item><p>Control siRNA compared to KDM4C siRNA #1</p></list-item><list-item><p>Control siRNA compared to KDM4C siRNA #2</p></list-item><list-item><p>Control siRNA compared to KDM4C siRNA #3</p></list-item></list></p></list-item><list-item><p>KDM4C levels (QC):<list list-type="bullet"><list-item><p>Control siRNA compared to KDM4C siRNA #1</p></list-item><list-item><p>Control siRNA compared to KDM4C siRNA #2</p></list-item><list-item><p>Control siRNA compared to KDM4C siRNA #3</p></list-item></list></p></list-item></list></p></list-item></list></p></list-item></list></p></list-item><list-item><p>Meta-analysis of original and replication attempt effect sizes:<list list-type="bullet"><list-item><p>Oil-Red-O staining for siRNA #1 and #2:<list list-type="bullet"><list-item><p>This replication attempt will perform the statistical analysis listed above, compute the effects sizes, compare them against the reported effect size in the original paper and use a meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot.<list list-type="bullet"><list-item><p>There is no originally reported data from siRNA #3, therefore it will not be included.</p></list-item></list></p></list-item></list></p></list-item><list-item><p>Western Blot:<list list-type="bullet"><list-item><p>The replication data will be presented as a mean with 95% confidence intervals and will include the original data point, calculated directly from the representative image, as a single point on the same plot for comparison.</p></list-item></list></p></list-item></list></p></list-item></list></sec><sec id="s2-3-6"><title>Known differences from the original study</title><list list-type="simple"><list-item><p>The replication will perform the Oil-Red-O quantification for all three siRNAs, not just #1 and #2 as presented in Supplemental Figure 8.</p></list-item></list></sec><sec id="s2-3-7"><title>Provisions for quality control</title><p>All data obtained from the experiment - raw data, data analysis, control data and quality control data - will be made publicly available, either in the published manuscript or as an open access dataset available on the Open Science Framework (<ext-link ext-link-type="uri" xlink:href="https://osf.io/vfsbo/">https://osf.io/vfsbo/</ext-link>).</p><list list-type="bullet"><list-item><p>Ponceau stains confirming protein transfer to membranes</p></list-item><list-item><p>STR profiling and mycoplasma testing results</p></list-item></list></sec><sec id="s2-3-8"><title>Power calculations</title><p>Note: details of all power calculations can be found at <ext-link ext-link-type="uri" xlink:href="https://osf.io/rb32p/?view_only=9044639bba8b4f03af6ea1b8454e8bb1">https://osf.io/rb32p/</ext-link></p></sec></sec><sec id="s2-4"><title>Protocol 1</title><sec id="s2-4-1"><title>Summary of original data</title><p>Note: data estimated from published figures.</p><p><table-wrap id="tblu2" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th colspan="2">Supplemental Figure 1: normalized WB band intensity (normalized to Vector)</th><th>Mean</th><th>SD</th><th>N</th></tr></thead><tbody><tr><td rowspan="6">IDH1<sup>WT</sup></td><td>H3K9me2</td><td>1.7</td><td>0.8</td><td>3</td></tr><tr><td>H3K9me3</td><td>1</td><td>0.2</td><td>3</td></tr><tr><td>K3K4me3</td><td>1.2</td><td>0.6</td><td>3</td></tr><tr><td>H3K27me3</td><td>0.4</td><td>0.3</td><td>3</td></tr><tr><td>H3K36me3</td><td>1.2</td><td>0.4</td><td>3</td></tr><tr><td>H3K27me2</td><td>0.8</td><td>0.4</td><td>3</td></tr><tr><td rowspan="6">IDH1<sup>R132H</sup></td><td>H3K9me2</td><td>7.9</td><td>2.5</td><td>3</td></tr><tr><td>H3K9me3</td><td>4.1</td><td>1.2</td><td>3</td></tr><tr><td>K3K4me3</td><td>3.4</td><td>0.8</td><td>3</td></tr><tr><td>H3K27me3</td><td>2.5</td><td>0.5</td><td>3</td></tr><tr><td>H3K36me3</td><td>1.7</td><td>0.8</td><td>3</td></tr><tr><td>H3K27me2</td><td>4.7</td><td>2.5</td><td>3</td></tr><tr><td rowspan="6">IDH2<sup>WT</sup></td><td>H3K9me2</td><td>3.2</td><td>1.1</td><td>3</td></tr><tr><td>H3K9me3</td><td>2.1</td><td>1.2</td><td>3</td></tr><tr><td>K3K4me3</td><td>1.9</td><td>0.3</td><td>3</td></tr><tr><td>H3K27me3</td><td>1.9</td><td>0.8</td><td>3</td></tr><tr><td>H3K36me3</td><td>1.4</td><td>0.4</td><td>3</td></tr><tr><td>H3K27me2</td><td>1.5</td><td>0.9</td><td>3</td></tr><tr><td rowspan="6">IDH2<sup>R172K</sup></td><td>H3K9me2</td><td>11.4</td><td>3.8</td><td>3</td></tr><tr><td>H3K9me3</td><td>4.9</td><td>1.6</td><td>3</td></tr><tr><td>K3K4me3</td><td>4</td><td>1.4</td><td>3</td></tr><tr><td>H3K27me3</td><td>3.6</td><td>1.6</td><td>3</td></tr><tr><td>H3K36me3</td><td>1.8</td><td>0.7</td><td>3</td></tr><tr><td>H3K27me2</td><td>5.4</td><td>3.7</td><td>3</td></tr></tbody></table></table-wrap></p><p><table-wrap id="tblu3" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th colspan="3">Figure 1B: 2HG/glutamate ratios</th></tr><tr><th/><th>Mean</th><th>Assumed N</th></tr></thead><tbody><tr><td>IDH1<sup>WT</sup></td><td>0.005</td><td>3</td></tr><tr><td>IDH1<sup>R132H</sup></td><td>0.052</td><td>3</td></tr><tr><td>IDH2<sup>WT</sup></td><td>0.023</td><td>3</td></tr><tr><td>IDH2<sup>R172K</sup></td><td>1.56</td><td>3</td></tr></tbody></table></table-wrap></p></sec><sec id="s2-4-2"><title>Test family</title><list list-type="bullet"><list-item><p>Western blot; Figure 1B/Supplemental Figure 1A: Note: Since we do not have the raw data, we were unable to perform power calculations using a MANOVA. We are approximating sample sizes with corrected one-way ANOVAs for each DV (normalized histone methylations).<list list-type="bullet"><list-item><p>Bonferroni-corrected one-way ANOVAs (one per DV) followed by Bonferroni corrected planned comparisons:<list list-type="bullet"><list-item><p>Wild-type IDH1 compared to IDH1<sup>R132H</sup>, collapsed across all histone lysine methylations.</p></list-item><list-item><p>Wild-type IDH2 compared to IDH2<sup>R172K</sup>, collapsed across all histone lysine methylations.<list list-type="bullet"><list-item><p>Note: Only H3K9me2 is being included since this is the histone modification with the largest effect size reported. A correlation among all the histone methylations will also be performed prior to performing the proposed analysis plan.</p></list-item></list></p></list-item></list></p></list-item></list></p></list-item><list-item><p>2HG/glutamate ratios; Figure 1B:<list list-type="bullet"><list-item><p>One-way ANOVA followed by Bonferroni-corrected pairwise comparisons for the following:<list list-type="bullet"><list-item><p>IDH1<sup>WT</sup> compared to IDH1<sup>R132H</sup>, for H3K9me2</p></list-item><list-item><p>IDH2<sup>WT</sup> compared to IDH2<sup>R172K</sup>, for H3K9me2</p></list-item></list></p></list-item></list></p></list-item></list></sec><sec id="s2-4-3"><title>Power calculations</title><list list-type="bullet"><list-item><p>Power calculations were performed using R software (version 3.2.2) (R <xref ref-type="bibr" rid="bib2">Core Team, 2015</xref>) and G*Power (version 3.1.7) (<xref ref-type="bibr" rid="bib5">Faul et al., 2007</xref>)</p></list-item><list-item><p>Partial η<sup>2</sup> calculated as in <xref ref-type="bibr" rid="bib9">Lakens (2013)</xref></p></list-item><list-item><p>Western blot calculations:<list list-type="bullet"><list-item><p>Note: Due to the large variance, these parametric tests are only used for comparison purposes. The sample size is based on the non-parametric tests also listed. For the ANOVA a Kruskal-Wallis would be performed as the non-parametric alternative, which would require an ~15% increase in sample size calculated for the parametric test listed.</p></list-item></list></p></list-item></list><p><table-wrap id="tblu4" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th colspan="6">One-way ANOVA: α=0.00833, 4 groupsα</th></tr></thead><tbody><tr><td>DV</td><td>F(3,8)</td><td>Partial η2</td><td>Effect size <italic>f</italic></td><td>A priori power</td><td>Total Sample Size</td></tr><tr><td>H3K9me2</td><td>10.486</td><td>0.79726</td><td>1.98302</td><td>92.1%<sup>1</sup></td><td>12<sup>1</sup></td></tr><tr><td>H3K9me3</td><td>7.0274</td><td>0.72492</td><td>1.62335</td><td>96.4%<sup>1</sup></td><td>16<sup>1</sup></td></tr><tr><td>H3K4me3</td><td>6.6197</td><td>0.71284</td><td>1.57556</td><td>95.1%<sup>1</sup></td><td>16<sup>1</sup></td></tr><tr><td>H3K27me3</td><td>6.0339</td><td>0.69351</td><td>1.50423</td><td>92.7%<sup>1</sup></td><td>16<sup>1</sup></td></tr><tr><td>H3K36me3</td><td>0.6276</td><td>0.19051</td><td>1.06125</td><td>90.2%</td><td>24</td></tr><tr><td>H3K79me2</td><td>3.0033</td><td>0.52969</td><td>1.07984<sup>2</sup></td><td>80.0%<sup>2</sup></td><td>24</td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><p><sup>1</sup> With 6 samples per group (24 total), achieved power is 99.9%.</p></fn><fn id="tblfn2"><p><sup>2</sup> Since the original effect size will not be detectable with the proposed sample size, this is the effect size that can be detected at 80% power with the given sample size. The original effect size was 0.48512.</p></fn></table-wrap-foot></table-wrap></p><p><table-wrap id="tblu5" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th colspan="5">Planned contrasts; two-tailed <italic>t</italic>-test: α=0.004167</th></tr></thead><tbody><tr><td>Group 1</td><td>Group 2</td><td>Effect size <italic>d</italic></td><td>A priori power</td><td>n/group</td></tr><tr><td>IDH1<sup>WT</sup></td><td>IDH1<sup>R132H</sup></td><td>3.34039</td><td>84.9%<sup>1</sup></td><td>5<sup>1</sup></td></tr><tr><td>IDH2<sup>WT</sup></td><td>IDH2<sup>R172K</sup></td><td>2.93138</td><td>87.3%</td><td>6</td></tr><tr><td colspan="5">Planned contrasts; two-tailed Wilcoxon-Mann-Whitney: α=0.025</td></tr><tr><td>Group 1</td><td>Group 2</td><td>Effect size <italic>d</italic></td><td>A priori power</td><td>n/group</td></tr><tr><td>IDH1<sup>WT</sup></td><td>IDH1<sup>R132H</sup></td><td>3.34039</td><td>80.9%<sup>2</sup></td><td>5<sup>2</sup></td></tr><tr><td>IDH2<sup>WT</sup></td><td>IDH2<sup>R172K</sup></td><td>2.93138</td><td>84.0%</td><td>6</td></tr></tbody></table><table-wrap-foot><fn id="tblfn3"><p><sup>1</sup> With 6 samples per group, achieved power is 95.3%.</p></fn><fn id="tblfn4"><p><sup>2</sup> With 6 samples per group, achieved power is 93.4%.</p></fn></table-wrap-foot></table-wrap></p><list list-type="bullet"><list-item><p>2HG/glutamate ratio calculations:<list list-type="bullet"><list-item><p>Note: The original data does not indicate the error associated with multiple biological replicates. To identify a suitable sample size, power calculations were performed using different levels of relative variance.</p></list-item></list></p></list-item></list><p><table-wrap id="tblu6" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th colspan="5">2%; one-way ANOVA: α=0.05, 4 groups</th></tr></thead><tbody><tr><td>F(3,8)</td><td>Partial η<sup>2</sup></td><td>Effect size <italic>f</italic></td><td>A priori power</td><td>Total Sample Size</td></tr><tr><td>7240.7</td><td>0.99963</td><td>52.11901</td><td>99.9%</td><td>8</td></tr><tr><td colspan="5">Planned comparisons; 2-tailed <italic>t</italic>-test: α=0.025</td></tr><tr><td>Group 1 versus</td><td>Group 2</td><td>Effect size <italic>d</italic></td><td>A priori power</td><td>n per group</td></tr><tr><td>IDH1<sup>WT</sup></td><td>IDH1<sup>R132H</sup></td><td>63.6182</td><td>99.9%</td><td>2</td></tr><tr><td>IDH2<sup>WT</sup></td><td>IDH2<sup>R172H</sup></td><td>69.6606</td><td>99.9%</td><td>2</td></tr></tbody></table></table-wrap></p><p><table-wrap id="tblu7" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th colspan="5">15%; one-way ANOVA: α=0.05, 4 groups</th></tr></thead><tbody><tr><td>F(3,8)</td><td>Partial η<sup>2</sup></td><td>Effect size <italic>f</italic></td><td>A priori power</td><td>Total Sample Size</td></tr><tr><td>128.72</td><td>0.97970</td><td>6.94772</td><td>99.9%</td><td>8</td></tr><tr><td colspan="5">Planned comparisons; 2-tailed <italic>t</italic>-test: α=0.025</td></tr><tr><td>Group 1 versus</td><td>Group 2</td><td>Effect size <italic>d</italic></td><td>A priori power</td><td>n per group</td></tr><tr><td>IDH1<sup>WT</sup></td><td>IDH1<sup>R132H</sup></td><td>8.48242</td><td>83.5%</td><td>2</td></tr><tr><td>IDH2<sup>WT</sup></td><td>IDH2<sup>R172H</sup></td><td>9.28808</td><td>88.4%</td><td>2</td></tr></tbody></table></table-wrap></p><p><table-wrap id="tblu8" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th colspan="5">28%; one-way ANOVA: α=0.05, 4 groups</th></tr></thead><tbody><tr><td>F(3,8)</td><td>Partial η2</td><td>Effect size <italic>f</italic></td><td>A priori power</td><td>Total Sample Size</td></tr><tr><td>36.942</td><td>0.93268</td><td>3.72201</td><td>99.9%</td><td>8</td></tr><tr><td colspan="5">Planned comparisons; 2-tailed <italic>t</italic>-test: α=0.025</td></tr><tr><td>Group 1 versus</td><td>Group 2</td><td>Effect size <italic>d</italic></td><td>A priori power</td><td>n per group</td></tr><tr><td>IDH1<sup>WT</sup></td><td>IDH1<sup>R132H</sup></td><td>4.54415</td><td>92.4%</td><td>3</td></tr><tr><td>IDH2<sup>WT</sup></td><td>IDH2<sup>R172H</sup></td><td>4.97576</td><td>95.9%</td><td>3</td></tr></tbody></table></table-wrap></p><p><table-wrap id="tblu9" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th colspan="5">40%; one-way ANOVA: α=0.05, 4 groups</th></tr></thead><tbody><tr><td>F(3,8)</td><td>Partial η2</td><td>Effect size <italic>f</italic></td><td>A priori power</td><td>Total Sample Size</td></tr><tr><td>18.102</td><td>0.87160</td><td>2.60542</td><td>96.0%</td><td>8</td></tr><tr><td colspan="5">Planned comparisons; 2-tailed <italic>t</italic>-test: α=0.025</td></tr><tr><td>Group 1 versus</td><td>Group 2</td><td>Effect size <italic>d</italic></td><td>A priori power</td><td>n per group</td></tr><tr><td>IDH1<sup>WT</sup></td><td>IDH1<sup>R132H</sup></td><td>3.18091</td><td>89.6%</td><td>4</td></tr><tr><td>IDH2<sup>WT</sup></td><td>IDH2<sup>R172H</sup></td><td>3.48303</td><td>94.2%</td><td>4</td></tr></tbody></table></table-wrap></p><p>In order to produce quantitative replication data, we will run the experiment six times. Each time we will quantify the 2HG/glutamate ratio. We will determine the standard deviation across the biological replicates and combine this with the reported value from the original study to simulate the original effect size. We will use this simulated effect size to determine the number of replicates necessary to reach a power of at least 80%. We will then perform additional replicates, if required, to ensure that the experiment has more than 80% power to detect the original effect.</p></sec></sec><sec id="s2-5"><title>Protocol 2</title><sec id="s2-5-1"><title>Summary of original data</title><p>Note: data estimated from published figures.</p><p><table-wrap id="tblu10" position="anchor"><table frame="hsides" rules="groups"><tbody><tr><td colspan="2">Figure 2A: 2HG/glutamate ratio</td><td rowspan="2">Assumed N</td></tr><tr><td/><td>Mean</td></tr><tr><td>Vector</td><td>0.1</td><td>3</td></tr><tr><td>IDH1<sup>R172K</sup></td><td>5.3</td><td>3</td></tr><tr><td>IDH2<sup>WT</sup></td><td>0.1</td><td>3</td></tr></tbody></table></table-wrap></p><p><table-wrap id="tblu11" position="anchor"><table frame="hsides" rules="groups"><tbody><tr><td colspan="5">Figure 2D: Relative expression of adipocyte markers</td></tr><tr><td colspan="2">Pparg</td><td>Mean</td><td>SD</td><td>N</td></tr><tr><td rowspan="2">Vector</td><td>Day 0</td><td>1.45</td><td>0.823</td><td>3</td></tr><tr><td>Day 4</td><td>13.992</td><td>0.816</td><td>3</td></tr><tr><td rowspan="2"><italic>IDH2</italic><sup>WT</sup></td><td>Day 0</td><td>2.521</td><td>1.076</td><td>3</td></tr><tr><td>Day 4</td><td>10.966</td><td>0.879</td><td>3</td></tr><tr><td rowspan="2"><italic>IDH2</italic><sup>R172K</sup></td><td>Day 0</td><td>1.134</td><td>0.823</td><td>3</td></tr><tr><td>Day 4</td><td>4.223</td><td>0.941</td><td>3</td></tr><tr><td colspan="2">Cebpa</td><td>Mean</td><td>SD</td><td>N</td></tr><tr><td rowspan="2">Vector</td><td>Day 0</td><td>1.123</td><td>0.421</td><td>3</td></tr><tr><td>Day 4</td><td>3.053</td><td>1.188</td><td>3</td></tr><tr><td rowspan="2"><italic>IDH2</italic><sup>WT</sup></td><td>Day 0</td><td>1.93</td><td>0.456</td><td>3</td></tr><tr><td>Day 4</td><td>4.807</td><td>0.565</td><td>3</td></tr><tr><td rowspan="2"><italic>IDH2</italic><sup>R172K</sup></td><td>Day 0</td><td>0.667</td><td>0.491</td><td>3</td></tr><tr><td>Day 4</td><td>0.246</td><td>0.21</td><td>3</td></tr><tr><td colspan="2">Adipoq</td><td>Mean</td><td>SD</td><td>N</td></tr><tr><td rowspan="2">Vector</td><td>Day 0</td><td>0</td><td>58.621</td><td>3</td></tr><tr><td>Day 4</td><td>572.414</td><td>193.103</td><td>3</td></tr><tr><td rowspan="2"><italic>IDH2</italic><sup>WT</sup></td><td>Day 0</td><td>0</td><td>58.621</td><td>3</td></tr><tr><td>Day 4</td><td>448.276</td><td>86.207</td><td>3</td></tr><tr><td rowspan="2"><italic>IDH2</italic><sup>R172K</sup></td><td>Day 0</td><td>0</td><td>58.621</td><td>3</td></tr><tr><td>Day 4</td><td>41.379</td><td>27.586</td><td>3</td></tr></tbody></table></table-wrap></p></sec><sec id="s2-5-2"><title>Test family</title><list list-type="bullet"><list-item><p>2HG/glutamate ratios; Figure 2A bottom:<list list-type="bullet"><list-item><p>One way ANOVA followed by Fisher’s LSD for the following comparison:<list list-type="bullet"><list-item><p>IDH2<sup>WT</sup> vs. IDH2<sup>R172K</sup></p></list-item></list></p></list-item></list></p></list-item><list-item><p>qRT-PCR; Figure 2D: Note: Since we did not have the raw data, we were unable to perform power calculations using a MANOVA. We are approximating the sample sizes with corrected one-way ANOVAs for each DV (gene).<list list-type="bullet"><list-item><p>Bonferroni-corrected one-way ANOVAs (one per gene) followed by Bonferroni corrected comparisons for Day 4 timepoints:<list list-type="bullet"><list-item><p><italic>IDH2</italic><sup>R172K</sup>compared to vector for each gene (3 comparisons total)</p></list-item><list-item><p><italic>IDH2</italic><sup>R172K</sup>compared to <italic>IDH2</italic><sup>WT</sup> for each gene (3 comparisons total)</p></list-item></list></p></list-item></list></p></list-item></list></sec><sec id="s2-5-3"><title>Power calculations</title><list list-type="bullet"><list-item><p>Power calculations were performed using R software (version 3.2.2) (R <xref ref-type="bibr" rid="bib2">Core Team, 2015</xref>) and G*Power (version 3.1.7) (<xref ref-type="bibr" rid="bib5">Faul et al., 2007</xref>)</p></list-item><list-item><p>Partial η<sup>2</sup> calculated as in <xref ref-type="bibr" rid="bib9">Lakens (2013)</xref></p></list-item><list-item><p>2HG/glutamate ratios:<list list-type="bullet"><list-item><p>Note: The original data does not indicate the error associated with multiple biological replicates. To identify a suitable sample size, power calculations were performed using different levels of relative variance.</p></list-item></list></p></list-item></list><p><table-wrap id="tblu12" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th colspan="5">2%; one-way ANOVA: α=0.05, 3 groups</th></tr></thead><tbody><tr><td>F(2,6)</td><td>Partial η<sup>2</sup></td><td>Effect size <italic>f</italic></td><td>A priori power</td><td>Total Sample Size</td></tr><tr><td>7214.5</td><td>0.99958</td><td>49.0188</td><td>99.9%</td><td>6</td></tr><tr><td colspan="5">Planned comparisons; two-tailed <italic>t-</italic>test: α=0.05</td></tr><tr><td>Group 1 versus</td><td>Group 2</td><td>Effect size <italic>d</italic></td><td>A priori power</td><td>n per group</td></tr><tr><td>IDH2<sup>R172H</sup></td><td>IDH2<sup>WT</sup></td><td>84.9383</td><td>99.9%</td><td>2</td></tr></tbody></table></table-wrap></p><p><table-wrap id="tblu13" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th colspan="5">15%; one-way ANOVA: α=0.05, 3 groups</th></tr></thead><tbody><tr><td>F(2,6)</td><td>Partial η2</td><td>Effect size <italic>f</italic></td><td>A priori power</td><td>Total Sample Size</td></tr><tr><td>128.26</td><td>0.97715</td><td>6.53866</td><td>99.9%</td><td>6</td></tr><tr><td colspan="5">Planned comparisons; two-tailed <italic>t</italic>-test: α=0.05</td></tr><tr><td>Group 1 versus</td><td>Group 2</td><td>Effect size <italic>d</italic></td><td>A priori power</td><td>n per group</td></tr><tr><td>IDH2<sup>R172H</sup></td><td>IDH2<sup>WT</sup></td><td>11.3252</td><td>99.8%</td><td>2</td></tr></tbody></table></table-wrap></p><p><table-wrap id="tblu14" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th colspan="5">28%; one-way ANOVA: α=0.05, 3 groups</th></tr></thead><tbody><tr><td>F(2,6)</td><td>Partial η2</td><td>Effect size <italic>f</italic></td><td>A priori power</td><td>Total Sample Size</td></tr><tr><td>36.809</td><td>0.92464</td><td>3.50285</td><td>98.5%</td><td>6</td></tr><tr><td colspan="5">Planned comparisons; two-tailed <italic>t</italic>-test: α=0.05</td></tr><tr><td>Group 1 versus</td><td>Group 2</td><td>Effect size <italic>d</italic></td><td>A priori power</td><td>n per group</td></tr><tr><td>IDH2<sup>R172H</sup></td><td>IDH2<sup>WT</sup></td><td>6.06704</td><td>84.2%</td><td>2</td></tr></tbody></table></table-wrap></p><p><table-wrap id="tblu15" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th colspan="5">40%; one-way ANOVA: α=0.05, 3 groups</th></tr></thead><tbody><tr><td>F(2,6)</td><td>Partial η2</td><td>Effect size <italic>f</italic></td><td>A priori power</td><td>Total Sample Size</td></tr><tr><td>18.036</td><td>0.85739</td><td>2.45194</td><td>85.1%</td><td>6</td></tr><tr><td colspan="5">Planned comparisons; two-tailed <italic>t</italic>-test: α=0.05</td></tr><tr><td>Group 1 versus</td><td>Group 2</td><td>Effect size <italic>d</italic></td><td>A priori power</td><td>n per group</td></tr><tr><td>IDH2<sup>R172H</sup></td><td>IDH2<sup>WT</sup></td><td>4.24688</td><td>96.6%</td><td>3</td></tr></tbody></table></table-wrap></p><p>In order to produce quantitative replication data, we will run the experiment five times. Each time we will quantify the 2HG/glutamate ratio. We will determine the standard deviation across the biological replicates and combine this with the reported value from the original study to simulate the original effect size. We will use this simulated effect size to determine the number of replicates necessary to reach a power of at least 80%. We will then perform additional replicates, if required, to ensure that the experiment has more than 80% power to detect the original effect.</p><list list-type="bullet"><list-item><p>qRT-PCR:<list list-type="bullet"><list-item><p>Note: Due to the large variance, these parametric tests are only used for comparison purposes. The sample size is based on the non-parametric tests also listed. For the ANOVA a Kruskal-Wallis would be performed as the non-parametric alternative, which would require an ~15% increase in sample size calculated for the parametric test listed.</p></list-item></list></p></list-item></list><p><table-wrap id="tblu16" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th colspan="5">Pparg</th></tr></thead><tbody><tr><td colspan="5">One-way ANOVA: α=0.0167, 3 groups</td></tr><tr><td>F(2,6)</td><td>Partial η<sup>2</sup></td><td>Effect size <italic>f</italic></td><td>A priori power</td><td>Total Sample Size</td></tr><tr><td>96.854</td><td>0.96996</td><td>5.68195</td><td>99.5%<sup>1</sup></td><td>6<sup>1</sup></td></tr><tr><td colspan="5">Planned comparisons; two-tailed <italic>t</italic>-test: α=0.0083</td></tr><tr><td>Group 1 versus</td><td>Group 2</td><td>Effect size <italic>d</italic></td><td>A priori power</td><td>n per group</td></tr><tr><td><italic>IDH2</italic><sup>R172H</sup></td><td>Vector</td><td>11.0921</td><td>99.9%<sup>2</sup></td><td>3<sup>2</sup></td></tr><tr><td><italic>IDH2</italic><sup>R172H</sup></td><td><italic>IDH2</italic><sup>WT</sup></td><td>7.40559</td><td>98.6%<sup>2</sup></td><td>3<sup>2</sup></td></tr><tr><td colspan="5">Planned comparisons; two-tailed Wilcoxon-Mann-Whitney: α=0.0083</td></tr><tr><td>Group 1 versus</td><td>Group 2</td><td>Effect size <italic>d</italic></td><td>A priori power</td><td>n per group</td></tr><tr><td><italic>IDH2</italic><sup>R172H</sup></td><td>Vector</td><td>11.0921</td><td>99.9%<sup>2</sup></td><td>3<sup>2</sup></td></tr><tr><td><italic>IDH2</italic><sup>R172H</sup></td><td><italic>IDH2</italic><sup>WT</sup></td><td>7.40559</td><td>96.9%<sup>2</sup></td><td>3<sup>2</sup></td></tr></tbody></table><table-wrap-foot><fn id="tblfn5"><p><sup>1</sup> With 5 samples per group (15 total), achieved power is 99.9%.</p></fn><fn id="tblfn6"><p><sup>2</sup> With 5 samples per group, achieved power is 99.9%.</p></fn></table-wrap-foot></table-wrap></p><p><table-wrap id="tblu17" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th colspan="5">Cebpa</th></tr></thead><tbody><tr><td colspan="5">One-way ANOVA: α=0.0167, 3 groups</td></tr><tr><td>F(2,6)</td><td>Partial η<sup>2</sup></td><td>Effect size <italic>f</italic></td><td>A priori power</td><td>Total Sample Size</td></tr><tr><td>26.843</td><td>0.89947</td><td>5.68195</td><td>90.5%<sup>1</sup></td><td>6<sup>1</sup></td></tr><tr><td colspan="5">Planned comparisons; two-tailed <italic>t</italic>-test: α=0.0083</td></tr><tr><td>Group 1 versus</td><td>Group 2</td><td>Effect size</td><td>A priori power</td><td>n per group</td></tr><tr><td><italic>IDH2</italic><sup>R172H</sup></td><td>Vector</td><td>3.29048</td><td>91.6%</td><td>5</td></tr><tr><td><italic>IDH2</italic><sup>R172H</sup></td><td><italic>IDH2</italic><sup>WT</sup></td><td>10.7011</td><td>99.9%<sup>2</sup></td><td>3<sup>2</sup></td></tr><tr><td colspan="5">Planned comparisons; two-tailed Wilcoxon-Mann-Whitney: α=0.0083</td></tr><tr><td>Group 1 versus</td><td>Group 2</td><td>Effect size <italic>d</italic></td><td>A priori power</td><td>n per group</td></tr><tr><td><italic>IDH2</italic><sup>R172H</sup></td><td>Vector</td><td>3.29048</td><td>89.0%</td><td>5</td></tr><tr><td><italic>IDH2</italic><sup>R172H</sup></td><td><italic>IDH2</italic><sup>WT</sup></td><td>10.7011</td><td>99.9%<sup>2</sup></td><td>3<sup>2</sup></td></tr></tbody></table><table-wrap-foot><fn id="tblfn7"><p><sup>1</sup> With 5 samples per group (15 total), achieved power is 99.9%.</p></fn><fn id="tblfn8"><p><sup>2</sup> With 5 samples per group, achieved power is 99.9%.</p></fn></table-wrap-foot></table-wrap></p><p><table-wrap id="tblu18" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th colspan="5">Adipoq</th></tr></thead><tbody><tr><td colspan="5">One-way ANOVA: α=0.0167, 3 groups</td></tr><tr><td>F(2,6)</td><td>Partial η<sup>2</sup></td><td>Effect size <italic>f</italic></td><td>A priori power</td><td>Total Sample Size</td></tr><tr><td>15.269</td><td>0.83579</td><td>2.25603</td><td>96.3%<sup>1</sup></td><td>9<sup>1</sup></td></tr><tr><td colspan="5">Planned comparisons; two-tailed <italic>t</italic>-test: α=0.0083</td></tr><tr><td>Group 1 versus</td><td>Group 2</td><td>Effect size</td><td>A priori power</td><td>n per group</td></tr><tr><td><italic>IDH2</italic><sup>R172H</sup></td><td>Vector</td><td>3.85001</td><td>87.8%<sup>2</sup></td><td>4<sup>2</sup></td></tr><tr><td><italic>IDH2</italic><sup>R172H</sup></td><td><italic>IDH2</italic><sup>WT</sup></td><td>6.35752</td><td>94.5%<sup>3</sup></td><td>3<sup>3</sup></td></tr><tr><td colspan="5">Planned comparisons; two-tailed Wilcoxon-Mann-Whitney: α=0.0083</td></tr><tr><td>Group 1 versus</td><td>Group 2</td><td>Effect size <italic>d</italic></td><td>A priori power</td><td>n per group</td></tr><tr><td><italic>IDH2</italic><sup>R172H</sup></td><td>Vector</td><td>3.85001</td><td>84.0%<sup>4</sup></td><td>4<sup>4</sup></td></tr><tr><td><italic>IDH2</italic><sup>R172H</sup></td><td><italic>IDH2</italic><sup>WT</sup></td><td>6.35752</td><td>90.8%<sup>3</sup></td><td>3<sup>3</sup></td></tr></tbody></table><table-wrap-foot><fn id="tblfn9"><p><sup>1</sup> With 5 samples per group (15 total), achieved power is</p></fn><fn id="tblfn10"><p>99.9%.</p></fn><fn id="tblfn11"><p><sup>2</sup> With 5 samples per group, achieved power is 97.9%.</p></fn><fn id="tblfn12"><p><sup>3</sup> With 5 samples per group, achieved power is 99.9%.</p></fn><fn id="tblfn13"><p><sup>4</sup> With 5 samples per group, achieved power is 96.8%.</p></fn></table-wrap-foot></table-wrap></p></sec></sec><sec id="s2-6"><title>Protocol 3</title><sec id="s2-6-1"><title>Summary of original data</title><p>Note: data estimated from published figures.</p><p><table-wrap id="tblu19" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th colspan="2">Figure 4D and S8A: Western Blot</th><th>Band intensity (normalized to H3)</th></tr></thead><tbody><tr><td rowspan="4">KDM4C</td><td>Control siRNA</td><td>1</td></tr><tr><td><italic>KDM4C</italic> siRNA #1</td><td>0.5097<sup>1</sup></td></tr><tr><td><italic>KDM4C</italic> siRNA #2</td><td>0.2767<sup>1</sup></td></tr><tr><td><italic>KDM4C</italic> siRNA #3</td><td>0.0249<sup>2</sup></td></tr><tr><td rowspan="2">H3K9me3</td><td>Control siRNA</td><td>1</td></tr><tr><td><italic>KDM4C</italic> siRNA</td><td>0.3695<sup>2</sup></td></tr></tbody></table><table-wrap-foot><fn id="tblfn14"><p><sup>1</sup> These values were normalized to ß-Actin as seen in Supplemental Figure 8A.</p></fn><fn id="tblfn15"><p><sup>2</sup> These values were normalized to total H3 as seen in Figure 4D. Also there is no data for siRNAs #1 and #2. We have assumed similar values for siRNA #3 for the purposes of these calculations.</p></fn></table-wrap-foot></table-wrap></p><p><table-wrap id="tblu20" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Supplemental Figure 8B: Oil-Red-O quantification</th><th>Mean</th><th>SD</th><th>N</th></tr></thead><tbody><tr><td>Control</td><td>1.06</td><td>0.03</td><td>3</td></tr><tr><td>siRNA #1</td><td>0.42</td><td>0.15</td><td>3</td></tr><tr><td>siRNA #2</td><td>0.69</td><td>0.09</td><td>3</td></tr><tr><td>siRNA #3<sup>1</sup></td><td>0.69</td><td>0.09</td><td>3</td></tr></tbody></table><table-wrap-foot><fn id="tblfn16"><p><sup>1</sup> There is no data for siRNA #3. We have assumed similar values as siRNA #2 for the purposes of these calculations.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="s2-6-2"><title>Test family</title><list list-type="bullet"><list-item><p>Western blot; Figure 4D and S8A: Note: Since we did not have the raw data, we were unable to perform power calculations using a MANOVA. We are approximating the sample sizes with corrected one-way ANOVAs for each DV (normalized protein).<list list-type="bullet"><list-item><p>One-way ANOVAs followed by Bonferroni corrected comparisons:<list list-type="bullet"><list-item><p>H3K9me3 levels in control siRNA compared to each <italic>KDM4C</italic> siRNA (3 comparisons total)</p></list-item><list-item><p><italic>KDM4C</italic> levels in control siRNA compared to each KDM4C siRNA (3 comparisons total)</p></list-item></list></p></list-item></list></p></list-item><list-item><p>Quantification of Oil-Red-O staining; Figure S8B:<list list-type="bullet"><list-item><p>One way ANOVA followed by Bonferroni corrected comparisons:<list list-type="bullet"><list-item><p>Control siRNA compared to <italic>KDM4C</italic> siRNA #1</p></list-item><list-item><p>Control siRNA compared to <italic>KDM4C</italic> siRNA #2</p></list-item><list-item><p>Control siRNA compared to <italic>KDM4C</italic> siRNA #3</p></list-item></list></p></list-item></list></p></list-item></list></sec><sec id="s2-6-3"><title>Power calculations</title><list list-type="bullet"><list-item><p>Power calculations were performed using R software (version 3.2.2) (R <xref ref-type="bibr" rid="bib2">Core Team, 2015</xref>) and G*Power (version 3.1.7) (<xref ref-type="bibr" rid="bib5">Faul et al., 2007</xref>).</p></list-item><list-item><p>Partial η<sup>2</sup> calculated as in <xref ref-type="bibr" rid="bib9">Lakens (2013)</xref>.</p></list-item><list-item><p>Western Blot<list list-type="bullet"><list-item><p>Note: The original data does not indicate the error associated with multiple biological replicates. To identify a suitable sample size, power calculations were performed using different levels of relative variance.</p></list-item></list></p></list-item></list><p><table-wrap id="tblu21" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th colspan="6">2%; One-way ANOVA: α=0.025, 4 groups α</th></tr></thead><tbody><tr><td>DV</td><td>F(3,8)</td><td>Partial η<sup>2</sup></td><td>Effect size <italic>f</italic></td><td>Power</td><td>Total sample size</td></tr><tr><td>H3K9me3</td><td>2114.7</td><td>0.99874</td><td>28.161</td><td>99.9%</td><td>8</td></tr><tr><td><italic>KDM4C</italic></td><td>3865.5</td><td>0.99931</td><td>38.073</td><td>99.9%</td><td>8</td></tr><tr><td colspan="6">Planned comparisons; two-tailed <italic>t</italic>-test: α=0.0083</td></tr><tr><td>DV</td><td>Group 1 versus</td><td>Group 2</td><td>Effect size <italic>d</italic></td><td>A priori power</td><td>n per group</td></tr><tr><td rowspan="3">H3K9me3</td><td>Control</td><td>KDM4C #1</td><td>53.099</td><td>99.9%</td><td>2</td></tr><tr><td>Control</td><td>KDM4C #2</td><td>53.099</td><td>99.9%</td><td>2</td></tr><tr><td>Control</td><td>KDM4C #3</td><td>53.099</td><td>99.9%</td><td>2</td></tr><tr><td rowspan="3">KDM4C</td><td>Control</td><td>KDM4C #1</td><td>42.407</td><td>99.9%</td><td>2</td></tr><tr><td>Control</td><td>KDM4C #2</td><td>62.552</td><td>99.9%</td><td>2</td></tr><tr><td>Control</td><td>KDM4C #3</td><td>84.335</td><td>99.9%</td><td>2</td></tr></tbody></table></table-wrap></p><p><table-wrap id="tblu22" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th colspan="6">15%; One-way ANOVA: α=0.025, 4 groups</th></tr></thead><tbody><tr><td>DV</td><td>F(3,8)</td><td>Partial η<sup>2</sup></td><td>Effect size <italic>f</italic></td><td>Power</td><td>Total sample size</td></tr><tr><td>H3K9me3</td><td>37.595</td><td>0.93377</td><td>3.7547</td><td>99.2%</td><td>8</td></tr><tr><td>KDM4C</td><td>68.72</td><td>0.96264</td><td>5.0764</td><td>99.9%</td><td>8</td></tr><tr><td colspan="6">Planned comparisons; two-tailed <italic>t</italic>-test: α=0.0083</td></tr><tr><td>DV</td><td>Group 1 versus</td><td>Group 2</td><td>Effect size <italic>d</italic></td><td>A priori power</td><td>n per group</td></tr><tr><td rowspan="3">H3K9me3</td><td>Control</td><td>KDM4C #1</td><td>7.0800</td><td>97.8%</td><td>3</td></tr><tr><td>Control</td><td>KDM4C #2</td><td>7.0800</td><td>97.8%</td><td>3</td></tr><tr><td>Control</td><td>KDM4C #3</td><td>7.0800</td><td>97.8%</td><td>3</td></tr><tr><td rowspan="3">KDM4C</td><td>Control</td><td>KDM4C #1</td><td>5.6543</td><td>88.5%</td><td>3</td></tr><tr><td>Control</td><td>KDM4C #2</td><td>8.3403</td><td>99.6%</td><td>3</td></tr><tr><td>Control</td><td>KDM4C #3</td><td>11.245</td><td>99.9%</td><td>3</td></tr></tbody></table></table-wrap></p><p><table-wrap id="tblu23" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th colspan="6">28%; One-way ANOVA: α=0.025, 4 groups</th></tr></thead><tbody><tr><td>DV</td><td>F(3,8)</td><td>Partial η<sup>2</sup></td><td>Effect size <italic>f</italic></td><td>Power</td><td>Total sample size</td></tr><tr><td>H3K9me3</td><td>10.789</td><td>0.80182</td><td>2.0114</td><td>98.7%</td><td>12</td></tr><tr><td>KDM4C</td><td>19.722</td><td>0.88089</td><td>2.7195</td><td>89.2%</td><td>8</td></tr><tr><td colspan="6">Planned comparisons; two-tailed <italic>t</italic>-test: α=0.0083</td></tr><tr><td>DV</td><td>Group 1 versus</td><td>Group 2</td><td>Effect size <italic>d</italic></td><td>A priori power</td><td>n per group</td></tr><tr><td rowspan="3">H3K9me3</td><td>Control</td><td>KDM4C #1</td><td>3.7928</td><td>86.8%</td><td>4</td></tr><tr><td>Control</td><td>KDM4C #2</td><td>3.7928</td><td>86.8%</td><td>4</td></tr><tr><td>Control</td><td>KDM4C #3</td><td>3.7928</td><td>86.8%</td><td>4</td></tr><tr><td rowspan="3">KDM4C</td><td>Control</td><td>KDM4C #1</td><td>3.0291</td><td>85.9%</td><td>5</td></tr><tr><td>Control</td><td>KDM4C #2</td><td>4.4680</td><td>95.8%</td><td>4</td></tr><tr><td>Control</td><td>KDM4C #3</td><td>6.0240</td><td>92.1%</td><td>3</td></tr></tbody></table></table-wrap></p><p><table-wrap id="tblu24" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th colspan="6">40%; One-way ANOVA: α=0.025, 4 groups</th></tr></thead><tbody><tr><td>DV</td><td>F(3,8)</td><td>Partial η<sup>2</sup></td><td>Effect size <italic>f</italic></td><td>Power</td><td>Total sample size</td></tr><tr><td>H3K9me3</td><td>5.2868</td><td>0.66472</td><td>1.4080</td><td>80.2%</td><td>12</td></tr><tr><td>KDM4C</td><td>9.6637</td><td>0.78373</td><td>1.9037</td><td>97.6%</td><td>12</td></tr><tr><td colspan="6">Planned comparisons; two-tailed <italic>t</italic>-test: α=0.0083</td></tr><tr><td>DV</td><td>Group 1 versus</td><td>Group 2</td><td>Effect size <italic>d</italic></td><td>A priori power</td><td>n per group</td></tr><tr><td rowspan="3">H3K9me3</td><td>Control</td><td>KDM4C #1</td><td>2.6550</td><td>87.2%</td><td>6</td></tr><tr><td>Control</td><td>KDM4C #2</td><td>2.6550</td><td>87.2%</td><td>6</td></tr><tr><td>Control</td><td>KDM4C #3</td><td>2.6550</td><td>87.2%</td><td>6</td></tr><tr><td rowspan="3">KDM4C</td><td>Control</td><td>KDM4C #1</td><td>2.1204</td><td>85.6%</td><td>8</td></tr><tr><td>Control</td><td>KDM4C #2</td><td>3.1276</td><td>88.3%</td><td>5</td></tr><tr><td>Control</td><td>KDM4C #3</td><td>4.2168</td><td>93.3%</td><td>4</td></tr></tbody></table></table-wrap></p><p>In order to produce quantitative replication data, we will run the experiment three times. Each time we will quantify band intensity. We will determine the standard deviation of band intensity across the biological replicates and combine this with the reported value from the original study to simulate the original effect size. We will use this simulated effect size to determine the number of replicates necessary to reach a power of at least 80%. We will then perform additional replicates, if required, to ensure that the experiment has more than 80% power to detect the original effect.</p><list list-type="bullet"><list-item><p>Oil-Red-O staining:<list list-type="bullet"><list-item><p>Note: Due to the large variance, these parametric tests are only used for comparison purposes. The sample size is based on the non-parametric tests also listed. For the ANOVA a Kruskal-Wallis would be performed as the non-parametric alternative, which would require an ~15% increase in sample size calculated for the parametric test listed.</p></list-item></list></p></list-item></list><p><table-wrap id="tblu25" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th colspan="5">One-way ANOVA: α=0.05, 4 groups</th></tr></thead><tbody><tr><td>F(3,8)</td><td>Partial eta<sup>2</sup></td><td>Effect size <italic>f</italic></td><td>Power</td><td>Total Sample Size</td></tr><tr><td>20.939</td><td>0.88703</td><td>2.8022</td><td>97.8%<sup>1</sup></td><td>8<sup>1</sup></td></tr></tbody></table><table-wrap-foot><fn id="tblfn17"><p><sup>1</sup> With 3 samples per group (12 total), achieved power is 99.9%.</p></fn></table-wrap-foot></table-wrap></p><p><table-wrap id="tblu26" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th colspan="5">Planned comparisons; two-tailed Wilcoxon-Mann-Whitney: α=0.0167</th></tr></thead><tbody><tr><td colspan="5">Power Calculations</td></tr><tr><td>Group 1</td><td>Group 2</td><td>Effect size <italic>d</italic></td><td>Power</td><td>n/group</td></tr><tr><td>Control</td><td>KDM4C #1</td><td>5.9168</td><td>96.9%</td><td>3</td></tr><tr><td>Control</td><td>KDM4C #2</td><td>5.5156</td><td>93.3%</td><td>3</td></tr><tr><td>Control</td><td>KDM4C #3</td><td>5.5156</td><td>93.3%</td><td>3</td></tr><tr><td colspan="5">Planned comparisons; two-tailed <italic>t</italic>-test: α=0.0167</td></tr><tr><td>Group 1</td><td>Group 2</td><td>Effect size <italic>d</italic></td><td>Power</td><td>n/group</td></tr><tr><td>Control</td><td>KDM4C #1</td><td>5.9168</td><td>97.7%</td><td>3</td></tr><tr><td>Control</td><td>KDM4C #2</td><td>5.5156</td><td>95.6%</td><td>3</td></tr><tr><td>Control</td><td>KDM4C #3</td><td>5.5156</td><td>95.6%</td><td>3</td></tr></tbody></table></table-wrap></p></sec></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank Courtney Soderberg at the Center for Open Science for assistance with statistical analyses. We would also like to thanks the following companies for generously donating reagents to the Reproducibility Project: Cancer Biology; American Type and Tissue Collection (ATCC), Applied Biological Materials, BioLegend, Charles River Laboratories, Corning Incorporated, DDC Medical, EMD Millipore, Harlan Laboratories, LI-COR Biosciences, Mirus Bio, Novus Biologicals, Sigma-Aldrich, and System Biosciences (SBI).</p></ack><sec id="s3" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="conflict" id="conf1"><p>ADR: Cancer Metabolism Facility at Sanford Burnham Prebys Medical Discovery Institute is a Science Exchange associated laboratory</p></fn><fn fn-type="conflict" id="conf2"><p>DAS: Cancer Metabolism Facility at Sanford Burnham Prebys Medical Discovery Institute is a Science Exchange associated laboratory</p></fn><fn fn-type="conflict" id="conf3"><p>OZ: Cancer Metabolism Facility at Sanford Burnham Prebys Medical Discovery Institute is a Science Exchange associated laboratory</p></fn><fn fn-type="conflict" id="conf4"><p>PA-B: Functional Genomics Core at Sanford Burnham Prebys Medical Discovery Institute is a Science Exchange associated laboratory</p></fn><fn fn-type="conflict" id="conf5"><p>C-CC: Functional Genomics Core at Sanford Burnham Prebys Medical Discovery Institute is a Science Exchange associated laboratory</p></fn><fn fn-type="conflict" id="conf6"><p>The other authors declare that no competing interests exist.</p></fn><fn fn-type="conflict" id="conf7"><p>RP:CB: EI, FT, JL, NP: Employed by and hold shares in Science Exchange Inc</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>ADR, Drafting or revising the article</p></fn><fn fn-type="con" id="con2"><p>DAS, Drafting or revising the article</p></fn><fn fn-type="con" id="con3"><p>OZ, Drafting or revising the article</p></fn><fn fn-type="con" id="con4"><p>PA-B, Drafting or revising the article</p></fn><fn fn-type="con" id="con5"><p>C-CC, Drafting or revising the article</p></fn><fn fn-type="con" id="con6"><p>DAR-G, Drafting or revising the article</p></fn><fn fn-type="con" id="con7"><p>RP:CB, Conception and design, Drafting or revising the article</p></fn></fn-group></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akbay</surname><given-names>EA</given-names></name><name><surname>Moslehi</surname><given-names>J</given-names></name><name><surname>Christensen</surname><given-names>CL</given-names></name><name><surname>Saha</surname><given-names>S</given-names></name><name><surname>Tchaicha</surname><given-names>JH</given-names></name><name><surname>Ramkissoon</surname><given-names>SH</given-names></name><name><surname>Stewart</surname><given-names>KM</given-names></name><name><surname>Carretero</surname><given-names>J</given-names></name><name><surname>Kikuchi</surname><given-names>E</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Cohoon</surname><given-names>TJ</given-names></name><name><surname>Murray</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Uno</surname><given-names>K</given-names></name><name><surname>Fisch</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>K</given-names></name><name><surname>Gurumurthy</surname><given-names>S</given-names></name><name><surname>Gliser</surname><given-names>C</given-names></name><name><surname>Choe</surname><given-names>S</given-names></name><name><surname>Keenan</surname><given-names>M</given-names></name><name><surname>Son</surname><given-names>J</given-names></name><name><surname>Stanley</surname><given-names>I</given-names></name><name><surname>Losman</surname><given-names>JA</given-names></name><name><surname>Padera</surname><given-names>R</given-names></name><name><surname>Bronson</surname><given-names>RT</given-names></name><name><surname>Asara</surname><given-names>JM</given-names></name><name><surname>Abdel-Wahab</surname><given-names>O</given-names></name><name><surname>Amrein</surname><given-names>PC</given-names></name><name><surname>Fathi</surname><given-names>AT</given-names></name><name><surname>Danial</surname><given-names>NN</given-names></name><name><surname>Kimmelman</surname><given-names>AC</given-names></name><name><surname>Kung</surname><given-names>AL</given-names></name><name><surname>Ligon</surname><given-names>KL</given-names></name><name><surname>Yen</surname><given-names>KE</given-names></name><name><surname>Kaelin</surname><given-names>WG</given-names></name><name><surname>Bardeesy</surname><given-names>N</given-names></name><name><surname>Wong</surname><given-names>KK</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice</article-title><source>Genes &amp; Development</source><volume>28</volume><fpage>479</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1101/gad.231233.113</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Core Team</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>R: a language and environment for statistical computing. r foundation for statistical computing</article-title><uri xlink:href="http://www.R-project.org/">http://www.R-project.org/</uri></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duncan</surname><given-names>CG</given-names></name><name><surname>Barwick</surname><given-names>BG</given-names></name><name><surname>Jin</surname><given-names>G</given-names></name><name><surname>Rago</surname><given-names>C</given-names></name><name><surname>Kapoor-Vazirani</surname><given-names>P</given-names></name><name><surname>Powell</surname><given-names>DR</given-names></name><name><surname>Chi</surname><given-names>J-T</given-names></name><name><surname>Bigner</surname><given-names>DD</given-names></name><name><surname>Vertino</surname><given-names>PM</given-names></name><name><surname>Yan</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation</article-title><source>Genome Research</source><volume>22</volume><fpage>2339</fpage><lpage>2355</lpage><pub-id pub-id-type="doi">10.1101/gr.132738.111</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Errington</surname><given-names>TM</given-names></name><name><surname>Iorns</surname><given-names>E</given-names></name><name><surname>Gunn</surname><given-names>W</given-names></name><name><surname>Tan</surname><given-names>FE</given-names></name><name><surname>Lomax</surname><given-names>J</given-names></name><name><surname>Nosek</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>An open investigation of the reproducibility of cancer biology research</article-title><source>eLife</source><volume>3</volume><pub-id pub-id-type="doi">10.7554/eLife.04333</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faul</surname><given-names>F</given-names></name><name><surname>Erdfelder</surname><given-names>E</given-names></name><name><surname>Lang</surname><given-names>AG</given-names></name><name><surname>Buchner</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>G*power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences</article-title><source>Behavior Research Methods</source><volume>39</volume><fpage>175</fpage><lpage>191</lpage></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Figueroa</surname><given-names>ME</given-names></name><name><surname>Abdel-Wahab</surname><given-names>O</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Ward</surname><given-names>PS</given-names></name><name><surname>Patel</surname><given-names>J</given-names></name><name><surname>Shih</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Bhagwat</surname><given-names>N</given-names></name><name><surname>Vasanthakumar</surname><given-names>A</given-names></name><name><surname>Fernandez</surname><given-names>HF</given-names></name><name><surname>Tallman</surname><given-names>MS</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Wolniak</surname><given-names>K</given-names></name><name><surname>Peeters</surname><given-names>JK</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Choe</surname><given-names>SE</given-names></name><name><surname>Fantin</surname><given-names>VR</given-names></name><name><surname>Paietta</surname><given-names>E</given-names></name><name><surname>Löwenberg</surname><given-names>B</given-names></name><name><surname>Licht</surname><given-names>JD</given-names></name><name><surname>Godley</surname><given-names>LA</given-names></name><name><surname>Delwel</surname><given-names>R</given-names></name><name><surname>Valk</surname><given-names>PJM</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name><name><surname>Levine</surname><given-names>RL</given-names></name><name><surname>Melnick</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation</article-title><source>Cancer Cell</source><volume>18</volume><fpage>553</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2010.11.015</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kernytsky</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Hansen</surname><given-names>E</given-names></name><name><surname>Schalm</surname><given-names>S</given-names></name><name><surname>Straley</surname><given-names>K</given-names></name><name><surname>Gliser</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Travins</surname><given-names>J</given-names></name><name><surname>Murray</surname><given-names>S</given-names></name><name><surname>Dorsch</surname><given-names>M</given-names></name><name><surname>Agresta</surname><given-names>S</given-names></name><name><surname>Schenkein</surname><given-names>DP</given-names></name><name><surname>Biller</surname><given-names>SA</given-names></name><name><surname>Su</surname><given-names>SM</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Yen</surname><given-names>KE</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition</article-title><source>Blood</source><volume>125</volume><fpage>296</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1182/blood-2013-10-533604</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krell</surname><given-names>D</given-names></name><name><surname>Mulholland</surname><given-names>P</given-names></name><name><surname>Frampton</surname><given-names>AE</given-names></name><name><surname>Krell</surname><given-names>J</given-names></name><name><surname>Stebbing</surname><given-names>J</given-names></name><name><surname>Bardella</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>IDH mutations in tumorigenesis and their potential role as novel therapeutic targets</article-title><source>Future Oncology (London, England)</source><volume>9</volume><fpage>1923</fpage><lpage>1935</lpage><pub-id pub-id-type="doi">10.2217/fon.13.143</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lakens</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs</article-title><source>Frontiers in Psychology</source><volume>4</volume><fpage>863</fpage><pub-id pub-id-type="doi">10.3389/fpsyg.2013.00863</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Londono Gentile</surname><given-names>T</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Lodato</surname><given-names>PM</given-names></name><name><surname>Tse</surname><given-names>S</given-names></name><name><surname>Olejniczak</surname><given-names>SH</given-names></name><name><surname>Witze</surname><given-names>ES</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name><name><surname>Wellen</surname><given-names>KE</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>DNMT1 is regulated by ATP-citrate lyase and maintains methylation patterns during adipocyte differentiation</article-title><source>Molecular and Cellular Biology</source><volume>33</volume><fpage>3864</fpage><lpage>3878</lpage><pub-id pub-id-type="doi">10.1128/MCB.01495-12</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Ward</surname><given-names>PS</given-names></name><name><surname>Kapoor</surname><given-names>GS</given-names></name><name><surname>Rohle</surname><given-names>D</given-names></name><name><surname>Turcan</surname><given-names>S</given-names></name><name><surname>Abdel-Wahab</surname><given-names>O</given-names></name><name><surname>Edwards</surname><given-names>CR</given-names></name><name><surname>Khanin</surname><given-names>R</given-names></name><name><surname>Figueroa</surname><given-names>ME</given-names></name><name><surname>Melnick</surname><given-names>A</given-names></name><name><surname>Wellen</surname><given-names>KE</given-names></name><name><surname>O’Rourke</surname><given-names>DM</given-names></name><name><surname>Berger</surname><given-names>SL</given-names></name><name><surname>Chan</surname><given-names>TA</given-names></name><name><surname>Levine</surname><given-names>RL</given-names></name><name><surname>Mellinghoff</surname><given-names>IK</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>IDH mutation impairs histone demethylation and results in a block to cell differentiation</article-title><source>Nature</source><volume>483</volume><fpage>474</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.1038/nature10860</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKenney</surname><given-names>AS</given-names></name><name><surname>Levine</surname><given-names>RL</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Isocitrate dehydrogenase mutations in leukemia</article-title><source>The Journal of Clinical Investigation</source><volume>123</volume><fpage>3672</fpage><lpage>3677</lpage><pub-id pub-id-type="doi">10.1172/JCI67266</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sasaki</surname><given-names>M</given-names></name><name><surname>Knobbe</surname><given-names>CB</given-names></name><name><surname>Munger</surname><given-names>JC</given-names></name><name><surname>Lind</surname><given-names>EF</given-names></name><name><surname>Brenner</surname><given-names>D</given-names></name><name><surname>Brüstle</surname><given-names>A</given-names></name><name><surname>Harris</surname><given-names>IS</given-names></name><name><surname>Holmes</surname><given-names>R</given-names></name><name><surname>Wakeham</surname><given-names>A</given-names></name><name><surname>Haight</surname><given-names>J</given-names></name><name><surname>You-Ten</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>WY</given-names></name><name><surname>Schalm</surname><given-names>S</given-names></name><name><surname>Su</surname><given-names>SM</given-names></name><name><surname>Virtanen</surname><given-names>C</given-names></name><name><surname>Reifenberger</surname><given-names>G</given-names></name><name><surname>Ohashi</surname><given-names>PS</given-names></name><name><surname>Barber</surname><given-names>DL</given-names></name><name><surname>Figueroa</surname><given-names>ME</given-names></name><name><surname>Melnick</surname><given-names>A</given-names></name><name><surname>Zúñiga-Pflücker</surname><given-names>J-C</given-names></name><name><surname>Mak</surname><given-names>TW</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics</article-title><source>Nature</source><volume>488</volume><fpage>656</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1038/nature11323</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turcan</surname><given-names>S</given-names></name><name><surname>Rohle</surname><given-names>D</given-names></name><name><surname>Goenka</surname><given-names>A</given-names></name><name><surname>Walsh</surname><given-names>LA</given-names></name><name><surname>Fang</surname><given-names>F</given-names></name><name><surname>Yilmaz</surname><given-names>E</given-names></name><name><surname>Campos</surname><given-names>C</given-names></name><name><surname>Fabius</surname><given-names>AWM</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Ward</surname><given-names>PS</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name><name><surname>Kaufman</surname><given-names>A</given-names></name><name><surname>Guryanova</surname><given-names>O</given-names></name><name><surname>Levine</surname><given-names>R</given-names></name><name><surname>Heguy</surname><given-names>A</given-names></name><name><surname>Viale</surname><given-names>A</given-names></name><name><surname>Morris</surname><given-names>LGT</given-names></name><name><surname>Huse</surname><given-names>JT</given-names></name><name><surname>Mellinghoff</surname><given-names>IK</given-names></name><name><surname>Chan</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype</article-title><source>Nature</source><volume>483</volume><fpage>479</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1038/nature10866</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venneti</surname><given-names>S</given-names></name><name><surname>Felicella</surname><given-names>MM</given-names></name><name><surname>Coyne</surname><given-names>T</given-names></name><name><surname>Phillips</surname><given-names>JJ</given-names></name><name><surname>Gorovets</surname><given-names>D</given-names></name><name><surname>Huse</surname><given-names>JT</given-names></name><name><surname>Kofler</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Tihan</surname><given-names>T</given-names></name><name><surname>Sullivan</surname><given-names>LM</given-names></name><name><surname>Santi</surname><given-names>M</given-names></name><name><surname>Judkins</surname><given-names>AR</given-names></name><name><surname>Perry</surname><given-names>A</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Histone 3 lysine 9 trimethylation is differentially associated with isocitrate dehydrogenase mutations in oligodendrogliomas and high-grade astrocytomas</article-title><source>Journal of Neuropathology and Experimental Neurology</source><volume>72</volume><fpage>298</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1097/NEN.0b013e3182898113</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>PS</given-names></name><name><surname>Patel</surname><given-names>J</given-names></name><name><surname>Wise</surname><given-names>DR</given-names></name><name><surname>Abdel-Wahab</surname><given-names>O</given-names></name><name><surname>Bennett</surname><given-names>BD</given-names></name><name><surname>Coller</surname><given-names>HA</given-names></name><name><surname>Cross</surname><given-names>JR</given-names></name><name><surname>Fantin</surname><given-names>VR</given-names></name><name><surname>Hedvat</surname><given-names>CV</given-names></name><name><surname>Perl</surname><given-names>AE</given-names></name><name><surname>Rabinowitz</surname><given-names>JD</given-names></name><name><surname>Carroll</surname><given-names>M</given-names></name><name><surname>Su</surname><given-names>SM</given-names></name><name><surname>Sharp</surname><given-names>KA</given-names></name><name><surname>Levine</surname><given-names>RL</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate</article-title><source>Cancer Cell</source><volume>17</volume><fpage>225</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2010.01.020</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>PS</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Cross</surname><given-names>JR</given-names></name><name><surname>Abdel-Wahab</surname><given-names>O</given-names></name><name><surname>Levine</surname><given-names>RL</given-names></name><name><surname>Schwartz</surname><given-names>GK</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization</article-title><source>The Journal of Biological Chemistry</source><volume>288</volume><fpage>3804</fpage><lpage>3815</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.435495</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Kim</surname><given-names>S-H</given-names></name><name><surname>Ito</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name> <surname>,</surname> </name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Xiao</surname><given-names>M-T</given-names></name><name><surname>Liu</surname><given-names>L-x</given-names></name><name><surname>Jiang</surname><given-names>W-q</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>J-y</given-names></name><name><surname>Bin</surname><given-names>W</given-names></name><name><surname>Frye</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>Y-h</given-names></name><name><surname>Lei</surname><given-names>Q-y</given-names></name><name><surname>Guan</surname><given-names>K-L</given-names></name><name><surname>Zhao</surname><given-names>S-m</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases</article-title><source>Cancer Cell</source><volume>19</volume><fpage>17</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2010.12.014</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Moore</surname><given-names>LM</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Yung</surname><given-names>WKA</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma</article-title><source>Neuro-Oncology</source><volume>15</volume><fpage>1114</fpage><lpage>1126</lpage><pub-id pub-id-type="doi">10.1093/neuonc/not087</pub-id></element-citation></ref></ref-list></back><sub-article article-type="article-commentary" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.10860.002</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Davidson</surname><given-names>Irwin</given-names></name><role>Reviewing editor</role><aff id="aff5"><institution>Institut de Génétique et de Biologie Moléculaire et Cellulaire</institution>, <country>France</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Thank you for submitting your work entitled &quot;Registered report: IDH mutation impairs histone demethylation and results in a block to cell differentiation&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Irwin Davidson (Reviewing Editor) and Randy Schekman (Senior Editor).</p><p>The reviewers have discussed the reviews with one another and the Reviewing editor has drafted this decision to help you prepare a revised submission.</p><p>Summary:</p><p>The reviewers found this proposed study to have important impact on the functional consequences of the frequently occurring IDH mutations and their mode of action. The provided protocol appears complete, but several points concerning the statistical methods remain to be clarified.</p><p>Essential revisions:</p><p>Normality and homoscedasticity will be assessed using adequate tests and methods. However what kind of transformation do the authors plan to apply in case of skewed data? Do the authors have an idea of how the data could be skewed? Similarly, which test do the authors intend to apply in case of non-normal data?</p><p>Power calculations assume normally distributed data. In the opposite case non parametric tests will be used with much less power. Power calculations should be taken with caution, as they are performed according to an optimistic scenario.</p><p>Protocol 1:</p><p>The authors should clarify if the MANOVA analyses are planned to analyze the results of western blots and that:</p><p>a) Response variables are intensities measured for H3K9me2, H3K9me3, etc.;b) The factor of variability is the cohort with 5 different levels: control, IDH1<sup>-WT</sup>, IDH1 mutant, IDH2<sup>-WT</sup>, IDH2 mutant;c) Contrasts to be tested are the ones listed under the subsection “Confirmatory analysis plan” (H3K9me2, WT vs. mutant, etc.).</p><p>Clarifications should be made for each model used in this protocol, as it is not always clear how the suggested model fits the data. The same comments hold true for the other protocols, for example the 2HG/glutamate ratios where there is only one response variable and a factor of variability with 5 levels with 2 tested contrasts.</p><p>Protocol 2:</p><p>For the 2HG/glutamate ratio, please describe the model (one factor with three levels, one contrast?).</p><p>For the qRT-PCR, is it a per-gene model? What are the response variables? Please clarify.</p><p>Protocol 3:</p><p>Again please clarify the MANOVA model (response variable, factor levels, contrasts).</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.10860.003</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p><italic>Essential revisions: Normality and homoscedasticity will be assessed using adequate tests and methods. However what kind of transformation do the authors plan to apply in case of skewed data? Do the authors have an idea of how the data could be skewed? Similarly, which test do the authors intend to apply in case of non-normal data?</italic></p><p>We have included the potential of a logarithmic transformation in case of skewed data in the revised manuscript. This might be the case with the 2HG/glutamate ratios that are listed in the protocols, which only show representative images, but display them on a log scale, which suggests the data might be skewed.</p><p>In the case of non-normal data, the revised manuscript includes the non-parametric tests that would be applied. When there is reason to suspect that a non-parametric test might be applied, such as a large difference in variance between the groups being tested, we have included non-parametric as well as parametric power calculations as described in response to the second question.</p><p><italic>Power calculations assume normally distributed data. In the opposite case non parametric tests will be used with much less power. Power calculations should be taken with caution, as they are performed according to an optimistic scenario.</italic> </p><p>We agree and understand the limitations of using the original data we have been able to obtain, or estimate, as a basis for the sample size for the replication attempt. We also agree that some of the assumptions made are according to an optimistic scenario. However, we hope that by performing power calculations using non-parametric tests, when there is reason to believe the data would violate the assumptions of a parametric test, we will ensure the sample size used for the replication study will be suitable for a parametric test (what we aim to perform if possible) or the non-parametric test (what we quite possible will need to perform). Further, as pointed out, this still stands risk of decreased power depending on the nature of the replication data (such as if there is normal distribution) in order to perform the proposed comparisons. Additionally, we have revised the analysis plans and power calculations to reflect the proposed models and contrasts, including the potential non-parametric tests that might be performed.</p><p><italic>Protocol 1: The authors should clarify if the MANOVA analyses are planned to analyze the results of western blots and that:</italic></p><p> <italic>a) Response variables are intensities measured for H3K9me2, H3K9me3, etc.;b) The factor of variability is the cohort with 5 different levels: control, IDH1<sup>-WT</sup>, IDH1 mutant, IDH2<sup>-WT</sup>, IDH2 mutant;c) Contrasts to be tested are the ones listed under the subsection “Confirmatory analysis plan” (H3K9me2, WT vs. mutant, etc.).</italic></p><p> <italic>Clarifications should be made for each model used in this protocol, as it is not always clear how the suggested model fits the data. The same comments hold true for the other protocols, for example the 2HG/glutamate ratios where there is only one response variable and a factor of variability with 5 levels with 2 tested contrasts. Protocol 2: For the 2HG/glutamate ratio, please describe the model (one factor with three levels, one contrast?).</italic></p><p><italic>For the qRT-PCR, is it a per-gene model? What are the response variables? Please clarify. Protocol 3: Again please clarify the MANOVA model (response variable, factor levels, contrasts).</italic></p><p>Thank you for this suggestion. We have included the model of each proposed analysis plan, to reflect the DV, IV, and contrasts proposed. Additionally, we have revised the analysis plans and power calculations to reflect the proposed models and contrasts, included the potential non-parametric tests that might be performed.</p></body></sub-article></article>